

SWISS BIOTECH DAY 2025

© Swiss Biotech Association

May 5-6, 2025
Congress Center Basel

Host and event manager:



Logistics and marketing partner:

bamconn

Conference program at a glance

Monday, May 5, 2025

08:00-09:45	Citeline pre event (by invitation only)	Room Osaka/Samarkand
09:30	Early bird badge pick up	Foyer South, level 0
10:00-11:00	Swiss Biotech Association general assembly	Room Singapore
11:00	Registration opens	Foyer South, level 0
11:00-11:45	Media conference (media only)	Room Rio
11:00-18:45	Exhibition	Foyer level 2 and Eventhall, level 0 p. 56
	Global Village	Eventhall, level 0 p. 25
	Partnering	Room San Francisco, room Sydney & Gallery Foyer South p. 7
11:30-13:30	Lunch	Levels 0 and 2 p. 7
12:30-14:00	Plenary session I	Room Montreal p. 9
14:00-14:45	Poster presentations	Levels 0, 2 and 3 p. 64
14:00-15:00	Coffee break	Levels 0 and 2

Parallel tracks

14:30-16:30 Emerging biotech company presentations Room Singapore p. 10 	14:30-16:30 Clinical stage biotech company presentations Room Montreal p. 12 	14:30-18:00 Commercial stage biotech company presentations Room Osaka/Samarkand p. 14	14:30-18:15 Panel discussions MCH Lounge 14:30-15:15 Panel 1 p. 16 15:30-16:15 Panel 4 p. 16 16:30-17:15 Panel 10 p. 17 17:30-18:15 Panel 13 p. 17
16:45-17:30 p. 11 Pitch 1: Nucleate	16:45-18:30 Panel 9 & pitch 3: Digital & healthtech chapter p. 13		
17:45-18:30 p. 11 Pitch 2: Venture Leader			

18:00-18:45	International reception of the Global Village	Eventhall, level 0 p. 29
18:45-21:00	Evening reception	Levels 0 and 2 



Sunday, May 4, 2025

17:30-20:30	Welcome reception	Alte Markthalle Basel
-------------	-------------------	-----------------------

Kindly supported by   

14:30-18:15 Panel discussions Marriott room 1+2 14:30-15:15 Panel 2 p. 18 15:30-16:15 Panel 5 p. 18 16:30-17:15 Panel 11 p. 19 17:30-18:15 Panel 14 p. 19	14:30-18:15 Panel discussions Marriott room 3+4+5 14:30-15:15 Panel 3 p. 20 15:30-16:15 Panel 6 p. 20 16:30-17:15 Panel 12 p. 21 17:30-18:15 Panel 15 p. 21	14:30-18:15 Panel discussions Room Rio 15:30-17:00 Panel 7 & pitch 4: Microbiome p. 22 17:30-18:15 Panel 16 p. 23	14:30-17:45 Global Village track Verseau 15:30-16:15 Panel 8 p. 24 16:45-17:45 Pitch 5: Global Village international session p. 24
---	---	---	--

Conference program at a glance

Tuesday, May 6, 2025

07:15	Registration opens	<i>Foyer South, level 0</i>
07:30-17:00	Partnering	<i>Room San Francisco, room Sydney & Gallery Foyer South p. 7</i>
09:00-17:00	Exhibition	<i>Foyer level 2 and Eventhall, level 0 p. 56</i>
	Global Village	<i>Eventhall, level 0 p. 25</i>

09:00-09:45	Panel discussions & Pitching sessions			
	Panel 17 <i>Room Singapore</i> p. 32		Panel 18 <i>MCH Lounge</i> p. 32	
			Panel 19 <i>Marriott room 1+2</i> p. 33	Pitch 6: Investors <i>Marriott room 3+4+5</i> p. 33
				Workshop Trialize <i>Room Rio</i> p. 34
				Global Village plenary session <i>Verseau</i> p. 34
10:00-12:00	Plenary session II		<i>Room Montreal p. 35</i>	
12:00-12:45	Poster presentations		<i>Levels 0, 2 and 3 p. 64</i>	
12:00-14:00	Lunch		<i>Levels 0 and 2 p. 7</i>	

Parallel tracks							
12:30-16:30 Emerging biotech company presentations <i>Room Singapore p. 36</i> 	12:30-16:45 Clinical stage biotech company presentations <i>Room Montreal p. 37</i> 	12:30-16:45 Commercial stage company presentations <i>Room Osaka/Samarkand p. 38</i>	12:15-16:45 Panel discussions <i>MCH Lounge</i> 12:15-13:45 Panels: Industrial biotech chapter p. 39 14:00-14:45 Panel 24 p. 40 15:00-15:45 Panel 28 p. 40 16:00-16:45 Panel 32 p. 41	12:30-16:45 Presentations panels <i>Marriott room 1+2</i> 12:30-13:45 Commercial stage company presentations p. 42 14:00-14:45 Panel 25 p. 42 15:00-15:45 Panel 29 p. 43 16:00-16:45 Panel 33 p. 43	12:15-16:45 Panel discussions <i>Marriott room 3+4+5</i> 12:15-13:45 Pitch 8 & panel 21: Lab automation p. 44 14:00-14:45 Panel 26 p. 45 15:00-15:45 Panel 30 p. 45 16:00-16:45 Panel 34 p. 46	13:00-15:45 Panel discussions <i>Room Rio</i> 13:00-13:45 Panel 22 p. 47 14:00-14:45 Panel 27 p. 48 15:00-15:45 Panel 31 p. 48	12:00-13:45 Global Village track <i>Verseau</i> 12:00-12:45 Joint panel session p. 49 13:00-13:45 Panel 23 p. 49
15:30-16:30	Market place of the Global Village		<i>Eventhall, level 0 p. 29</i>				
16:30-18:30	Farewell reception		<i>Foyer level 2</i>				



Welcome reception

Welcome reception

Markthalle Basel

Sunday, May 4, 2025 | 17:30 - 20:30 | Markthalle Basel, Steinentorberg 20

The Swiss Biotech Day will once again provide a platform in Basel for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing.

This inaugural gathering provides a prime networking opportunity, allowing attendees to connect and engage with peers before the event officially starts. Join more than 1'500 other participants who have signed up for this reception for an aperitif and an informal fun networking evening in anticipation of the lively days ahead.

Kindly supported by   



Housekeeping notes

Food will be served at the times and locations below. Beverages are available in all areas throughout the event.

Monday, May 5, 2025

Eventhall, level 0	Foyer, level 2
11:30 - 13:30 Lunch	12:00 - 13:30 Lunch
18:00 - 19:00 International reception in the Global Village	
19:00 - 21:00 Evening reception 	19:00 - 21:00 Evening reception 

Tuesday, May 6, 2025

Eventhall, level 0	Foyer, level 2
12:00 - 14:00 Lunch 	12:00 - 14:00 Lunch 
15:30 - 16:30 Market place in the Global Village	
	16:30 - 18:30 Farewell reception

You will find the coffee bike in the Eventhall on level 0 for your much-needed daily dose of caffeine, kindly supported by 

Help yourself to some Swiss treats, available on level 1 near the partnering area.

Pre-scheduled one-to-one meetings:

Please check your individual meeting schedule for times and locations of your confirmed meetings. Need help? Please see the partnering help desk in **room San Francisco** on level 3.



supported by 

Free WiFi
SSID: Free Messe Basel
Free SMS-Login
(one Login for each device)

 **X**
#swissbiotechday
 **LinkedIn**
#swissbiotechday

Sweepstake

Collect the flag stickers and win attractive prizes

How to play

- ▶ Collect the 25 stickers of the Global Village delegations (see p. 25).
- ▶ Glue the stickers on the right name on the inside.
- ▶ Trade your duplicate stickers e.g. during your 1:1 meetings or networking breaks.
- ▶ Once completed, bring this sheet to the Swiss Biotech Association booths #1 and #114 or the Life Science Cares booth #SC5.

We select winners three times

- ▶ Evening reception, **May 5, 18:45**, Foyer, Congress Center, level 2
- ▶ Market Place reception, **May 6, 16:00**, Eventhall, level 0
- ▶ Farewell reception, **May 6, 17:00**, Foyer, Congress Center, level 2

You can win:

▶ Swiss Biotech Day 2026 tickets

Join us at the next Swiss Biotech Day on May 4-5, 2026 with a free ticket.



▶ Glacier Express ride

Take a journey over daredevil viaducts, through countless tunnels and unique landscapes, and enjoy a dinner in Zermatt.

▶ Hot air balloon flight

Enjoy the breathtaking view of glittering lakes, fairytale nature, magnificent mountain scenery, and dine where you land.



▶ Lucerne boat tour

Be indulged with an overnight stay in Lucerne and take in unbeatable views of the city and mountains from the lake as you cruise by.

▶ Eurovision Song Contest 2025 entries

Experience the ESC final in the Arena Plus.

Plenary session

12:30-14:00 Plenary session I

Room Montreal

Moderation: **Monika Jones**

12:30 Welcome local host

Kaspar Sutter, Head of the Department of Economic, Social and Environmental Affairs, Canton of Basel-Stadt

12:35 Welcome organizer

Michael Altorfer, CEO, Swiss Biotech Association

12:45 Botnar Institute of Immune Engineering (BIIE)

Steven Wilson, CEO, & **Sai Reddy**, Scientific Director

13:00 Deep Tech Nation Switzerland Foundation

Dario My, Head Venture Hub Switzerland

13:15 Navigating the current environment as a biotechnology company – observations and tactics on capital raising, strategic collaborations and M&A

Part I

Host: **Kenneth Krisko**, Partner, Cooley

Panelists:

Avaleigh Milne, Global Head of Business Development Strategy & Practice, Pharma Partnering, F. Hoffmann-La Roche

Tahera Kan, Vice President, Head of Precision Medicine, Johnson & Johnson

Luca Santarelli, Founder, Chief Executive Officer, and Chairman of the Board, Windward Bio

13:40 Part II

Host: **Patrick Amstutz**, CEO, Molecular Partners, & President, Swiss Biotech Association

Panelists:

Richard Girling, Partner, Centerview Partners

Div Gupta, Partner, Cooley

David Urech, CEO, Numab Therapeutics

Emerging biotech companies

Presented by **PUREOS**
BIOVENTURES

Time	Company	Room Singapore
14:30	Pureos Bioventures	
14:45	NXI Therapeutics	
15:00	Salvina Therapeutics	
15:15	Tandem Therapeutics	
15:30	Stromal Therapeutics	
15:45	Mabylon	
16:00	Aukera Therapeutics	
16:15	Dimericon Therapeutics	

Moderation: **Dominik Escher**, Managing Partner, & **Anne Grahl**, Associate, Pureos Bioventures



Find details about the presenting companies here →

Pitching sessions

Presented by  Nucleate Switzerland

16:45-17:30 Pitch 1: Nucleate start-ups Room Singapore

BioPitch: Catalyzing innovation at Swiss Biotech Day with Nucleate

Discover groundbreaking innovations from Switzerland's early-stage life science start-ups at Nucleate Switzerland's pitching session. These start-ups, part of Nucleate's Activator program, are revolutionizing human health challenges. Run by academic trainees, Nucleate fosters technology commercialization, offering equity-free support and connecting budding entrepreneurs with a prestigious advisor network.

Moderation: **Börte Emiroglu**, Leadership member, Nucleate | **Ebru Topcu**, Leadership member, Nucleate | **Tianlan Cai**, Leadership member, Nucleate

Jury: **Katharina Kreymborg**, SVP, CSO, Partner, Curie.Bio | **Daniel Bode**, Analyst, Forbion

16:45 Introduction

16:50 Prabolis

17:11 CALDRE

16:57 Nexendia

17:18 InSEIT

17:04 UNOMR

17:25 Voting and closing remarks

Presented by  ventureleaders

17:45-18:30 Pitch 2: Venture Leaders Room Singapore

Meet the Venture Leaders Biotech 2025

Meet the 2025 Biotech Swiss National Startup Team before their exclusive roadshow to Boston! Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex Boston & New York and supported by the University of Basel, EPF Lausanne, ETH Zurich, Hansjörg Wyss, Kellershals Carrard, and VISCHER. Join us as we showcase the innovative spirit and potential of these exceptional startups.

Moderation: **Jordi Montserrat**, Co-founder and Managing Partner, Venturelab | **Maurice Stäheli**, Project Manager, Venturelab

17:45 Venture Leaders Biotech introduction

17:50 Abrinca Genomics

18:10 Encelta

17:54 Amporin Pharmaceuticals

18:14 HemostOD

17:58 Apricot Therapeutics

18:18 InkVivo Technologies

18:02 Aukera Therapeutics

18:22 Juvion Health Sciences

18:06 Enantios

18:26 Nerai Biosciences

Clinical stage companies

Presented by 

Time	Company	Room Montreal
14:30	Celonic	
14:45	Genevant	
15:00	Versameb	
15:15	ImmunOS Therapeutics	
15:30	Vir Biotechnology	
15:45	Curatis	
16:00	Muvon Therapeutics	
16:15	Legacy Healthcare	

Moderation: **Georg Blaser**, VP of Biologics Development Center, & **Thomas Francillette**, Director – Development & Process Optimization, Celonic Group



Find details about the presenting companies here →

Panel discussions & pitching sessions

Presented by  

16:45-18:30 Panel 9 & Pitch 3: Digital & healthtech chapter

Room Montreal

Harnessing AI & big data: The next frontier in biotech and healthcare

Artificial intelligence and big data are revolutionizing biotech and healthcare, driving breakthroughs in precision medicine, clinical decision-making, and drug discovery.

This panel will showcase how adaptive or autonomous AI models enhance decision-making and improve industry performance and productivity.

Additionally, the discussion will emphasize the importance of robust AI infrastructure in creating scalable, high-performance healthcare solutions, while also highlighting the necessity of strong, high-quality data for accurate AI concepts.

Experts will delve into advancements in clinical development productivity, patient data analytics, AI-powered diagnostics, and the agent-based concepts, while also highlighting local initiatives designed to foster collaboration and innovation in healthcare AI.

Moderation: **Pablo Nieto**, Principal, IQVIA

Panelists:

Eva-Maria Hempe, Head of Healthcare and Life Sciences EMEA, NVIDIA

Erwin Böttinger, Director, Wyss Center for Bio and Neuroengineering

Tom Baker, VP and GM, IQVIA Switzerland & Israel

Philippe Menu, EVP, Chief Medical Officer & Chief Product Officer, Sophia Genetics

AI & digital health: Startups shaping the future of healthcare

This pitching session highlights startups leveraging digital health technologies and AI to drive breakthroughs in healthcare, therapeutic development and personalized medicine. Presenters will explore how these technologies are pushing the boundaries of innovation, in combination with clinical trial platforms, brain health diagnostics, single-cell sequencing, genomic data management, robotics-integrated platforms and drug discovery solutions. Join experts and investors as they discuss how cutting-edge digital innovations are shaping the future of healthcare and techbio.

Moderation: **Carine Poussin**, Head of AI for Life Sciences, CSEM

Jury: **Eva-Maria Hempe**, Head of Healthcare and Life Sciences EMEA, NVIDIA |

Matthias Hermann, Head of Digital Health Fund, Tenity | **Ursula Costa**, Director, DayOne |

Tom Baker, VP and GM, IQVIA | **Philippe Menu**, EVP, Sophia Genetics

17:45 Introduction

17:50 inVirtuoLabs

17:55 Parithera

18:00 dEEGtal

18:05 Skyvor Medical

18:10 AlphaMol Science

18:15 GeneVault

18:20 Juvion Life Sciences

18:25 Voting and closing address

Commercial stage companies

Time	Company	Room Osaka/Samarkand
14:30	Belach Biotechnik	
14:45	CinnaGen	
15:00	Excellgene	
15:15	PSI CRO	
15:30	Labcorp	
15:45	Helbling	
16:00	Basilea Pharmaceutica	
16:15	BeiGene	
16:30	Break	
16:45	Cytiva	
17:00	Menarini Biotech	
17:15	Cube Biotech	
17:30	Associazione Life Sciences Competence Center	
17:45	TFS Health Science	

Moderation: **Marta Gehring**, Swiss Biotech Association



Find details about the presenting companies here →

SWISS+ BIOTECH™ Global Village

The power of international collaboration

Join our Global Village and connect your biotech cluster with the Swiss biotech ecosystem for lasting business ties.

Presented by:



Supported by:



Panel discussions

Presented by  **Fortrea**

14:30-15:15 Panel 1

MCH Lounge

Optimizing study outcomes: Creating an evidence-based value proposition for commercial success

This session delves into methods to improve study outcomes by combining scientific rigor with a commercially driven mindset, ensuring that clinical development meets the expectations of payers, health technology assessment requirements, and considerations of real-world evidence (RWE).

Furthermore, we will address the crucial function of real-world data (RWD), real-world evidence in enhancing clinical trial results, supporting market surveillance, long-term value for payers.

Moderation: **Laura Vidal Boixader**, Vice President, Therapeutic Strategy Leader, Fortrea

Panelists:

Juliane Bernholz, CEO, AM-Pharma

Adrian Cassidy, GMA Evidence Generation Head, Novartis

John Doyle, Chief Scientific Officer, Fortrea

Presented by  **KennedyFitch**  **headcount**

15:30-16:15 Panel 4

MCH Lounge

Next-gen biotech: Human capital (r)evolution: Mindset, skills & culture for a future-ready workforce

As science and biotech leap forward, what will it mean for people, skills and our values?

This panel explores the mindset, skills, and culture driving the future of biotech.

Beyond retention: What truly keeps biotech professionals engaged: purpose, leadership, career pathways, or something else?

- Flexibility vs. productivity: Can biotech have both? Will flexibility define the next era of biotech work culture and mindset?

- Adapting to biotech's evolution: How shifting business models, technology, and generational shifts shape skills and culture.

Moderation: **Oliver Kingdon**, Head of Recruitment, EMEA, Roche Pharmaceuticals

Panelists:

Annet Zippel, Partner, KennedyFitch

Maurice Thornton, General Manager, headcount

Sarah Holmes Klotz, Global Head of People and Culture Santhera

Franz-Werner Haas, CEO, Limmatech Biologics

Panel discussions

Presented by

 **LUMINANCE**
fostering meaningful growth

16:30-17:15 Panel 10

MCH Lounge

Advanced therapies: From research to patient access - opportunities and challenges

Advanced therapies hold great promise for patients, including those with rare diseases, but face a range of challenges, such as technological hurdles, regulatory and quality complexities, and access limitations. This panel addresses these challenges and explores innovative approaches and opportunities to overcome these obstacles, focusing also on how the collaboration between regulators, industry, and patients can improve access to advanced therapies.

Moderation: **Nathalie Schober-Ladani**, Head Commercial, Luminance Health

Panelists:

Julia Djonova, Leiterin Advanced Therapy Medicinal Products, Swissmedic

Ghada Ibrahim, President, PACRT-Geneva

Tom Eaton, Co-Founder, Limula

Joanna Hanley, Head Quality Assurance, Luminance Health

Presented by

 **Baker McKenzie.**

17:30-18:15 Panel 13

MCH Lounge

Navigating the future: Life sciences deal-making amid geopolitical headwinds

The session will dive into the current trends in life sciences deal-making and upcoming challenges due to the current geopolitical headwinds. We will be joined by experts from investment banking, biotech and big pharma to explore the challenges and opportunities that the industry currently faces. The discussion will delve into:

- The impact of the new U.S. administration on the industry
- How interest rate policies are shaping financial strategies
- Key insights on IPO trends and M&A activities
- Licensing opportunities and global influences, including China's biotech advancements

Moderation: **Julia Schieber**, Partner (Zurich); Baker McKenzie

Panelists:

Oren Livne, Partner (New York), Baker McKenzie

Lev Kogon, Vice President, Head of Business Development, Nykode Therapeutics

Konrad Gehrke, Director Healthcare Investment Banking, Bank of America

Panel discussions

Presented by **SARTORIUS**

14:30-15:15 Panel 2

Marriott Hotel room 1+2

Re-thinking downstream processing intensification: A new perspective

Due to rising costs and competition, the biopharma industry seeks cost, time, and resource savings while enhancing yield and quality. To stay competitive, therapeutic protein costs must drop below USD 50 / gram. Global challenges like aging populations and climate change pressure the industry to meet sustainability targets. Sartorius' PI technologies offer solutions, enabling robust implementation. This panel will discuss managing information for effective PI implementation, maximizing operational value, and exploring industry perspectives on manufacturing technologies.

Moderation: **Geert Lissens**, Head of PM Filtration & TFF Systems, Sartorius

Panelists:

Sonja Berensmeier, Chair of Bioseparation Engineering, TU Munich

Eduard Ayuso, Chief Technology Officer, Dinamiq

Presented by



15:30-16:15 Panel 5

Marriott Hotel room 1+2

Small molecule lead finding for challenging targets: Lessons from GLP-1 receptor modulators

G protein-coupled receptors (GPCRs) are not only one of the largest classes of signaling molecules in the human genome, they are also serving as target receptor for about one third of approved drugs. Sensing a great variety of different ligands from protons to proteins they also differ greatly in the likelihood to identify small molecule modulators ('druggability').

The panel will discuss past learnings and opportunities of our growing tool box in discovery research to tackle difficult GPCR and other targets.

Moderation: **Joerg Hueser**, Member Scientific Advisory Board, Axxam

Panelists:

Michael Hennig, CEO, leadXpro

Zoë Johnson, CSO/CDO, Molecule to Medicine

Frederic Bassilana, Executive Director Discovery Services, Novartis Biomedical Research

Panel discussions

Presented by **Cetacea CONSULTING** METRONOMIA

16:30-17:15 Panel 11

Marriott Hotel room 1+2

Beyond the protocol: Strategic insights for planning your first clinical trial

Clinical trials are complex—strategic planning essential! Discover insights for your first clinical trial with our panel of seasoned industry professionals. Learn how to navigate common challenges in quality, data management, vendor selection, and trial oversight to optimize trial execution. Don't miss this practical advice from experienced clinical leaders!

Moderation: **Cornelia Baumgartner**, Clinical Operations Specialist, Cetacea Clinical

Panelists:

Ulf Grawunder, CEO, T-CURX

Ludovic Moulin, Managing Director, ObelysQ

Dominik Hartl, Chief Medical Officer, GRANITE-BIO

Markus Niemeier, Managing Director, Metronomia Clinical Research

Presented by



17:30-18:15 Panel 14

Marriott Hotel room 1+2

From science to patients: Opportunities and new trends in ADCs

From science to patients: opportunities and new trends in ADCs

Moderation: **Jean Engela**, CEO, NBE-Therapeutics

Panelists can be found on our website

Find details about the panel discussions here →



Panel discussions

Presented by  **CITELINE**
a norstella company

14:30-15:15 Panel 3

Marriott Hotel room 3+4+5

Biotech investor strategy in a dynamic market

In this panel discussion, Citeline and leading European investors will discuss the latest trends that are shaping venture capital deployment in innovative biotech startups, both in Switzerland and beyond. With recent years seeing investment concentrated in fewer companies with larger raises, are VCs broadening their focus? Increasing competition in high-activity therapeutic areas and technologies leaves less room to add value, but remains a core focus for potential pharma partners. This session will help biotech leaders stay ahead of market dynamics and hone their deal-making pitch.

Moderation: **Kevin Grogan**, Managing Editor Europe, Commercial, Scrip

Panelists:

Anta Gkelou, Partner, Sofinnova Capital Strategy

Dani Bach, Managing Partner, Limani Partners

Jean-Philipp Kruse, Senior Director, Lilly Ventures

Presented by  **AliraHealth**
Patient-Enabled Solutions

15:30-16:15 Panel 6

Marriott Hotel room 3+4+5

From lab to market: The investor-innovator dynamic in biotech

Biotech innovation is a high-stakes game where ideas meet funding limits. In 2025, shifting investment cycles – from the metabolic disease boom to struggles in cell and gene therapies – reshape the landscape. Macroeconomic and political forces, including US research funding shifts and Europe's fragmented capital markets, add complexity. This panel explores how investors filter opportunities, which biotech sectors rise or fall, and what it takes to secure investment.

Moderation: **Joris Pezzini**, EVP, Biopharma, Alira Health

Panelists:

Pascale Eede, Associate, Apollo Health Ventures

Pierre Morgon, CEO, Ibox Therapeutics

Massimo Mineo, CEO, Neurolieve Biosciences

Kevin Hammon, Vice President, EQT Life Science

Panel discussions

Presented by  **MENARINI group**  **Cavenagh Health**

16:30-17:15 Panel 12

Marriott Hotel room 3+4+5

AMR: A threat to patients' lives and modern medicine – time for immediate actions and sustainable solutions

This panel addresses AMR as a critical threat to patients' lives and the future of modern medicine. Moving beyond awareness, it focuses on actionable steps to drive innovation, boost the weak antibiotic pipeline, and establish sustainable access through effective push and pull incentives. The discussion will highlight antibiotics' role as life-saving enablers, their economic value, and the urgent need to recognize their contribution across disease areas. It will also explore big pharma's role, private investment strategies, and how to build a sustainable innovation ecosystem focused around biotech startups. Finally, the panel will consider how Switzerland and international stakeholders can operationalize the recent UNGA declaration, turning global commitments into measurable progress.

Moderation: **Guillermo Tramontin**, Associate Partner, Cavenagh Health

Panelists:

Najy Alsayed, Global Therapeutic Area Head - Infectious Diseases Menarini Group

Damiano de Felice, Chief of External Affairs CARB-X

Deepali Patel, Director, International Policy, AMR Action Fund

Marc Gitzinger, CEO and Founder, BioVersys

Presented by  **BeiGene**

17:30-18:15 Panel 15

Marriott Hotel room 3+4+5

Enhancing Europe's role as a global hub for oncology trials

Over the last few years, Europe has experienced a decline in oncology clinical trial activity, losing ground to the US, China, and Australia. Despite an overall increase in global oncology trials, site activation timelines have lengthened, and patient access to new therapies has slowed. This panel discussion will convene key stakeholders to explore strategies for strengthening Europe's clinical trial ecosystem and reclaiming its leadership in global oncology research.

Moderation: **Rute Marques**, CEO, ROK Communications

Panelists:

Pilar de la Rocha Mur, Head of Clinical Operations, EMEA, BeiGene

Anna Maria Frustaci, ASST Grande Ospedale Metropolitano Niguarda Milan

David Alsadius, Solid Tumor Franchise Lead, IQVIA

Alexander Natz, Director General, EUCOPE

Panel discussions

Presented by  

15:30-17:00

Panel 7 & Pitch 4: Microbiome

Room Rio

Microbiome milestones: From market launch to future trends

Join us for a dynamic session featuring a panel discussion followed by an exciting pitching segment. Experts, investors, and biotech leaders will explore key achievements, challenges, and success factors in microbiome-based therapies. Gain valuable insights into the future of microbiome research and healthcare. Afterwards, innovative companies will present their cutting-edge solutions to a jury of experts.

Moderation: **Isma Hachi**, Director, IQVIA (overall moderation)
Tomas de Wouters, CEO, PharmaBiome (panel moderation)

Panelists:

Per Falk, CEO, GC Holdings

Isabelle de Cremoux, CEO, Seventure

Johanna Eliasson Vinterberg, Medical Director, Gastroenterology Therapeutic Area, Ferring Pharmaceuticals

Jonathan Chriqui, Chief Business Officer Maat Pharma

The pitching session aims to be an extension of the preceding panel with the goal to provide a platform for microbiome innovators in human health.

Moderation: **Isma Hachi**, Director, IQVIA

Jury:

Isabelle de Cremoux, CEO, Seventure

Per Falk, CEO, GC Holdings

Manuel Frankhauser, CEO, Seerave Foundation

Stefanie Zechner, Founder & Director, nextimpact

Isma Hachi, Director, IQVIA

Pitching companies:

Aurealis	REM Analytics
Exeliom Biosciences	Swipebiome
Microbalance	Trilliome
Mikrobiomik	Yoni Solutions

Panel discussions

Presented by 

17:30-18:15 Panel 16

Room Rio

CMC success factors for emerging biotechs

Join leaders from biotech, pharma, and CDMOs as they explore key CMC success factors across modalities — from small molecules to oligonucleotides, biologics, LNPs, and advanced delivery systems. This discussion will offer practical insights, share challenges, and highlight strategies to help biotechs scale, streamline, and accelerate development with technical and operational excellence.

Moderation: **Sonja Merkas**, Founder, Creator & Doer, Livinovea

Panelists:

Ed Yaworski, CTO, Genevant Sciences

Gabriella Rolli, CTO, TenPoint Therapeutics

Ivan Pogorelic, Head of CMC, Nxera Pharma

Michaela Freiberger, VP Oligo Manufacturing, Bachem

Find details about the panel discussions here →



Global Village track

Presented by  **SWISSmedic**

Verseau

15:30-16:15 Panel 8

How to reach more patients faster: The promise of international collaboration and shared regulatory approval pathways

International collaboration is a key element of the Swiss innovation landscape. Early support to build bridges between experts from different countries and collaborative international regulatory approval pathways, such as ACCESS and Orbis, result in faster access for patients. In this panel discussion we will share different perspectives and experiences and provide insights into the opportunities created for patients.

Moderation: **Eveline Trachsel**, Head of Medicinal Product Authorisation and Vigilance, Swissmedic, Swiss Agency for Therapeutic Products

Panelists:

Corinne Wenger, Head of Regulatory Affairs, Roche Pharma (Schweiz)

Sabine Ledderhose, Head of Regulatory Affairs, Astra Zeneca

Sergio Cantoreggi, Chief Scientific Officer, Sintetica

Presented by  **Swiss Biotech Association**

Verseau

16:45-17:45 Pitch 5: International session

Global innovation showcase: Startups from the Global Village

Explore cutting-edge biotech startups from around the world, developing innovative products and technologies to address global health challenges. Join us to discover the future of biotech, hear from visionary founders, and uncover exciting investment opportunities.

Moderation: **Maximilien Murone**, Liaison Basel | Northwestern Switzerland, Swiss Biotech Association

Jury: **Zoë Johnson**, CSO, Molecule to Medicine | **Frederic Levy**, CSO Debiopharm | **Kostas Kaloulis**, Partner, ND+ Capital | **Veronica Gambillara**, Partner, Pureos Bioventures | **Nikita Sharma**, Principal, Versant Ventures | **Daniela Couto**, General Partner, BGV

16:45 Introduction

16:50 T-CURX (Bavaria) 17:15 Softmining (Italy)

16:55 Amyl Therapeutics (Belgium) 17:20 Tatum Bioscience (Canada)

17:00 Deuteroncology (Belgium) 17:25 ILIAS Biologics (South Korea)

17:05 Mavatar (Nordic countries) 17:30 Araceli Biosciences (Oregon)

17:10 Adalid Sciences (Czechia) 17:35 Voting and closing remarks

Global Village

Presented by  **Swiss Biotech Association**

Supported by  **SWITZERLAND GLOBAL ENTERPRISE**  **Schweizerische Eidgenossenschaft**

Global Village

Eventhall

Welcome to the Global Village at the Swiss Biotech Day 2025 - The power of international collaboration

The Global Village, spearheaded by the **Swiss Biotech Association**, serves as a premier platform for fostering international collaboration and networking within the biotech and life sciences industries. In partnership with leading Swiss organizations, it offers a continuous, year-round gateway for global biotech clusters to forge and deepen strategic, long-term partnerships within Switzerland's thriving biotech ecosystem.

The **Global Village mission** is centered around:

- **Connecting global life sciences hubs with Swiss biotech leaders**
Use the **international reception (p. 29)** and **market place (p. 29)** to meet and connect with the international delegations, or simply visit them at their booth in the **Global Village area (p. 26)**.
- **Empowering international delegations**
Witness bilateral **roundtable discussions (p. 30)** tailored to international delegations looking to develop and strengthen long-term, sustainable business ties and collaborations with key decision-makers within the Swiss biotech ecosystem.
- **Driving collaborative excellence**
Join the **Global Village stream (pp. 24 & 49)**, including the **Global Village plenary session (p. 34)** where we showcase the power of international collaboration, promote the exchange of best practices, and support the development of joint initiatives that deliver mutual value and benefit all stakeholders involved.

Since its inception in 2022, the Global Village has attracted delegations from across **North and South America, Asia, Australia, and Europe**, reflecting its success in advancing global biotech collaboration.

This year, the Global Village is joined by a record number of **25 delegations** and all Swiss Biotech Day participants are welcome to attend and contribute to the planned sessions.



Find further information about the Global Village here →

Global Village

Booth Delegation

GV1 Oregon, USA 

Participating companies:
Araceli Biosciences, Dextronix, Genentech, Oregon Bioscience Association, Rewire AI, State of Oregon – Business Oregon

GV2 Spain   

Participating companies:
AseBio, Basque Health Cluster, BFlow, Biobide, Bioga, CIC bioGUNE, Cytes Biotechnologies, CZ Vaccines, GalChimia, Hiblab, Hifas da Terra, LiberaBio, Liof Pharma, Mikrobiomik, Protein Alternatives, Syspro, World Courier

GV3 Japan  

Participating companies:
Asahi Kasei Corporation, ASKA Pharmaceutical, Astellas Pharma, Daiichi Sankyo, EA Pharma, FUJIFILM Corporation, Genesis Healthcare, Maruho, Murata Manufacturing, Nitto-Denko, ROHTO Pharmaceutical, Swiss Business Hub Japan, Teijin Holdings Europe, TOMOEGAWA Corporation, Yokogawa Innovation Switzerland

GV4 Brazil 


Participating companies:
BioDecision Analytics, Brainlike, Fiocruz, Sindusfarma, Synvia

GV5 China  

Participating companies:
Biocytogen, Canton Biologics, Dachao Biotechnology, Eyebright Medical Technology (Beijing), Shandong Jincheng Pharmaceutical Group, Shanghai Medicilon, Sichuan Huiyu Pharmaceutical, Swiss Business Hub China, Xtalpi

GV6 Italy 

Participating companies:
Advaxia, Ampure, Biosphere, Exo Lab Italia, Genechron, Genenta Science, InSilicoTrials Technologies, Irbm, Italian Trade Agency, Regulatory Pharma Net, Security Pattern, Sense4Med, Service Biotech, Softmining, Studio Torta, Takis Biotech

GV7 India  

Participating companies:
Apollo Hospitals Educational and Research Foundation, Clinixel Life Sciences, Equine Biotech, Mestastop Solutions, OneSource CDMO, Persistent, Sai Life, Swiss Business Hub India, Zasya Lifesciences

Global Village

Booth Delegation

GV8 Iran 

Participating companies:
Aroko Bioengineering, AryoGen Pharmed, CinnaGen, NanoAlvand

GV9 Belgium  

Participating companies:
Amyl Therapeutics, Catalent Gosselies, Catalya, CER Groupe, Conveyxo, DeuterOncology, e-Proteins, Estetra, Euroscreen Fast, Genko, Inchinn Therapeutics, International Drugs Development Institute, Kaneka Eurogentec, Lambda-X High Tech, Q1 Scientific, Qualiblood, Salamander U, Straticell, Telemedicine Technologies, Wallonia Export and Investment Agency, Wallonia-Brussels International, Ynios Pharma

GV10 Netherlands 

Participating companies:
AM-Pharma, BioConnection, Biotech Booster, GenomeScan, Health Holland, Loyens & Loeff, LUO Automation, Medace, Mimetas, Murata Electronics Europe, NFIA, Oncode accelerator, QPS Netherlands, RVO, Single Cell Discoveries, Siron Clinical, Tiofarma, TU Delft, Vitroscan

GV11 Nordic countries   

Participating companies:
Celectricon, CuraCell, Cytel, HealthCatalyst, Invest in Skåne, Mavatar, MVA, Pelago Bioscience, Smile Incubator, SwedenBIO, Ventri Labs

GV12 North Carolina, USA 

Participating companies:
Adamas Nanotechnologies, AESARA, Codetta Bio, Economic Development Partnership of North Carolina, SmaBio Labs, Swabbot Solutions

GV13 Estonia  

Participating companies:
Enterprise Estonia Biotech, Gearbox Biosciences, Health Founders Estonia, Helmes Software Development, Lanmer, Menken Trials, Migrevention, Ministry of Foreign Affairs of Estonia, Raumedica Estonia, Tartu Biotechnology Park, TBD Pharmatech

GV14 Heidelberg-Mannheim region, Germany 

Participating companies:
AGC Biologics, BIMOVIS, bioRN Life Science Cluster, Heidelberg Pharma, Sciomics, Trans-Duodenal Concepts

Global Village

Booth Delegation

GV15 Rhineland-Palatinate, Germany



Participating companies:

biomindz Standortentwicklungsgesellschaft Mainz, Life Science Zentrum Mainz/ BioVation RLP, Midas Pharma, Ministry of Economic Affairs, Transport, Agriculture and Viniculture Rhineland-Palatinate, STRASSBURGER Filter

GV16 Czechia



Participating companies:

Adalid Sciences, DNAi, IOCB Tech, Prague.bio, Quinta Analytic, SCTbio

GV17 Taiwan



Participating companies:

Biomedical Translation Research Center (BioTReC), Academia Sinica, KriSan Biotech, Taiwan Bio Industry Organization

GV18 Greece



Participating companies:

ASTAT, Critica Pharmaceutical, Hellenic Biocluster, Oncolipsy, Pharmassist

GV19 Bavaria, Germany



Participating companies:

Bio^M Biotech Cluster Development, Invitris, IZB Martinsried, Tech Transfer at the University of Würzburg

GV20 Saxony, Germany



Participating companies:

biosaxony, Fraunhofer IZI, Intu Diagnostics, leap-up, Saxony Trade & Invest

GV21 Hong Kong



Participating companies:

InvestHK, Hong Kong-Shenzhen Innovation and Technology Park (HSITP), Office of Research and Knowledge Transfer Services (ORKTS) The Chinese University of Hong Kong, The Technology Transfer Unit (TTU) of the LKS Faculty of Medicine - The University of Hong Kong

GV22 Canada



Participating companies:

Dalriada Drug Discovery, Government of Canada/Trade Commissioner Service, KreaMedica, Lemay.ai, Solid State Pharma, Tatum Biosciences

Global Village

Booth Delegation

GV23 Australia



Participating companies:

Accelagen, Crux Biolabs, RDI Partners, Veritus Research

GV24 South Korea



Participating companies:

ANPOLY, Avataar, Decomposition, Deepsonbio, Eight, Embargo Media, Healthybody, Ilias, KOTRA, L-Base, Pohang City, Radahaim, Xbody

GV25 France



Participating companies:

Alcediag, Expertrials, HealthTech for Care, Lyophitech

May 5, 18:00-18:45 International reception

Eventhall

Join us for a dedicated networking reception at the Global Village, where participants can connect with 25 international delegations in a relaxed and engaging setting. The event will feature welcome remarks by Michael Altorfer, CEO of the Swiss Biotech Association, and a speech by Switzerland Global Enterprise (S-GE), a long-standing partner of the Global Village.

May 6, 15:30-16:30 Market place

Eventhall

The Market Place is the closing networking event of the Global Village, where international delegations will share drinks and snacks from their home countries—celebrating cultural diversity and global collaboration. Delegates will be invited to share their key achievements at Swiss Biotech Day and offer an outlook on future opportunities. The event will conclude with farewell speeches by Michael Altorfer, CEO, and Patrick Amstutz, President of the Board at the Swiss Biotech Association, including the announcement of this edition's Country Partnership of the Year.

Roundtable discussions

Please join us for roundtable discussions, aiming to facilitate partnerships and connect international representatives with the Swiss biotech industry for research, corporate collaborations, policy-making and investments.

Mon May 5	Roundtable 1 Eventhall (stage)	Roundtable 2 Verseau
14:15	Spain Switzerland as a guest nation in BIOSPAIN: How we can establish a framework for a permanent collaboration	
14:30		Taiwan Ecosystem collaboration & business connection between Taiwan and Switzerland
14:45		
15:00		
15:15	Nordic countries The Nordics and Switzerland innovating together: Translating innovation into biotech ventures	
15:30		Panel 8: How to reach more patients faster: The promise of international collaboration and shared regulatory approval pathways
15:45		
16:00	Japan Swiss-Japanese biotech synergies: Innovation, expansion & partnership across borders	See page 24
16:15		
16:30		
16:45	Canada The state of AI in drug discovery: Advances & ethics	Pitch 3: Global innovation showcase: Startups from the Global Village
17:00		
17:15		
17:30		See page 24

Roundtable discussions

Tue May 6	Roundtable 1 Eventhall (stage)	Roundtable 2 Verseau
12:00	Netherlands Organ-on-Chip: Implementation through collaboration between the Netherlands and Switzerland	Joint panel session Crossing borders: Strategies in global partnering and deal making for biotech
12:15		
12:30		See page 49
12:45		
13:00	Bavaria Bridging ecosystems: Empowering startups from pre-seed to scale-up in Bavaria and Switzerland (4 case studies)	Panel 23: I can't take my eyes off you: Swiss innovation and why it attracts international investors
13:15		
13:30		See page 49
13:45		
14:00	Oregon Oregon and Switzerland have formed a new journey of collaboration	India From India to the world: Biotech bridges with Swiss expertise
14:15		
14:30		
14:45	China From China's AI surge to Switzerland's pharma leadership: Accelerating the Sino-Swiss strategy for global impact in life sciences	Estonia Building large scale digital infrastructure for healthcare systems
15:00		

Panel discussions & pitching sessions

Presented by **Deloitte.****09:00-09:45 Panel 17****Room Singapore**

Navigating the challenging financing landscape: Strategies for growth and exit

Capital raising and financing has become a major challenge for scale-up companies in today's risk-off environment. Investors have started to scrutinize opportunities more holistically and credibility is achieved through profitability considerations and a viable scale-up plan; a pure growth case is no longer sufficient. What are the remaining opportunities for growth and exit? How can a path towards higher return on investment be clearly articulated to potential investors?

This panel will delve into the complexities of the current financing landscape, equipping biotech executives and entrepreneurs with the knowledge and tools needed to navigate the challenging financing landscape and achieve their objectives.

Moderation: **Liam Baynes**, Partner - Audit & Assurance for Life Sciences, Deloitte | **Enada Ismailaj**, Senior Manager - Strategy, Risk and Transaction, Deloitte

Panelists:

Matthias Bodenstedt, CFO, Moonlake**Jannis Fischer**, Co-Founder & CEO, Positrigo**Michael Hennig**, CEO, leadXpro**Oleg Parosin**, CEO, BioMedica**Jonas Zeller**, CFO, InnomedicaPresented by **CTC**  Swiss Biotech Association**09:00-09:45 Panel 18****MCH Lounge**

Shared responsibility for biotech growth: Uniting academia, industry, leaders, and HR to support talent in challenging times

As big pharma shifts priorities and biotech start-ups struggle, scientists and professionals seek new opportunities in the Swiss life science ecosystem. Are we ready to harness this talent? What skills are essential? How can academia, HR, industry, associations, and government collaborate to bridge the gap for innovation and social impact?

This panel unites stakeholders to tackle these questions and invites you to help shape the future of biotech talent in Switzerland. Join the conversation!

Moderation: **Natasha Konstantinova**, Head talent pool & Academy, Swiss Biotech Association

Panelists:

Peter Kilian, CEO, CTC Resourcing**Claire Beckers**, Postdoctoral Scientist, University of Zurich**Thomas Baumgart**, Founder, Alentis & Professor, University of Strasbourg

Panel discussions & pitching sessions

Presented by **Syneos Health****09:00-09:45 Panel 19****Marriott Hotel room 1+2**

Rethinking the fast lane: How Project Optimus impacts early oncology trials

This panel will explore the implications of implementing Project Optimus within early-stage oncology drug development. Discussion will focus on whether the initiative facilitates development acceleration through optimized dose selection, or whether it introduces potential delays in achieving key decision points.

Panelists will include representatives from the biotech sector, mid-sized pharmaceutical companies, a regulatory affairs expert, and a clinical oncologist specializing in early-phase oncology trials. Attendees will gain insights from diverse stakeholder perspectives and real-world experiences in applying Project Optimus principles across different oncology assets.

Moderation: **Jozsef Palatka**, VP, Medical Director, Syneos Health

Panelists:

Zohra Lomri, Executive Director Regulatory Affairs, Syneos Health

Further panelists can be found on our website

Presented by **Curie.Bio****09:00-09:45 Pitch 6****Marriott Hotel room 3+4+5**

Reverse pitch: What top biotech VCs are looking for

In this unique session, leading biotech VCs pitch their investment models to founders. Learn how each firm thinks about scientific risk, team, and path to clinic—and what sets them apart. A must-attend for anyone looking to raise capital or understand today's biotech venture landscape.

Moderation: **Nina Kreymborg**, Curie.Bio

Jury: **Patrick Amstutz**, CEO, Molecular Partners, & President, Swiss Biotech Association

09:00 Introduction**09:05** Curie.Bio**09:21** Forbion**09:13** Versant Ventures**09:29** BioGeneration Ventures**09:37** Closing remarks

Workshop & Global Village plenary

Presented by  Trialize

09:00-09:45 Workshop

Room Rio

Build your clinical study in 15 minutes with Trialize AI

See how a modern approach can shave months off your setup, save thousands of hours during execution while de-risking your research. We'll showcase how Trialize, an AI-driven clinical trial automation platform, can reduce setup times by over 50%, save more than \$300K per study, and ensure real-time data insights to minimize the risk of missing endpoints. Our platform easily integrates with legacy systems, offers predictive risk alerts, and enables adaptive protocol updates - all from a unified dashboard.

Moderation: **Stephane Ritty**, Trialize

Presenters:

Leonid Stoianov, Trialize

Philip Raeth, Trialize

Peter Daniel Ketelsen, Trialize

09:00-09:45 Global Village plenary

Verseau

Eureka: Funding for global R&D cooperation

This plenary session will spotlight EUREKA, the world's largest public network for international R&D and innovation, with a presence in over 45 countries. It will feature an introduction by the EUREKA Secretariat, followed by a discussion and testimonies from international biotech companies and EUREKA representatives. Moderated by Innosuisse, the session will include audience questions and conclude with an outlook on the Swiss Biotech Day 2026 and the Eureka Global Innovation Summit 2026.

Moderation: **Andreas Gut**, Innosuisse

Plenary session

10:00-12:00 Plenary session II

Room Montreal

Moderation: **Monika Jones**

10:00 **Opening remarks**

Michael Altorfer, CEO, Swiss Biotech Association

10:05 **Fireside chat**

Houman Ashrafian, Executive Vice President, Head of Research and Development, Sanofi

Moderated by **Patrick Amstutz**, CEO, Molecular Partners, & President, Swiss Biotech Association

10:35 **The biotech investment landscape: What's next for capital & growth?**

Host: **Seth Lewis**, Senior Vice President Investor Relations, Communications and Strategy, Molecular Partners

Panelists:

Ivo Staijen, Head of Public Equity, HBM Partners

Karen O'Reilly, Managing Director Healthcare Banking, TD Cowen

Charles Zhu, Managing Director, LifeSci Capital

Lazar Bojic, Vice President, Curie.Bio

11:05 **Swiss Biotech Report**

Severin Dressen, Director Zurich Zoo

Frederik Schmachtenberg, Partner, Global Life Sciences Lead for Financial Accounting Advisory Services, EY

11:30 **Swiss Biotech Success Stories Award**

Jürg Zürcher, jury president

Emerging biotech companies

Presented by **PUREOS**
BIOVENTURES

Time	Company	Room Singapore
12:30	Araris Biotech	
12:45	FimmCyte	
13:00	Inthera Bioscience	
13:15	metaLead Therapeutics	
13:30	Allegria Therapeutics	
13:45	Atopia Therapeutics	
14:00	Fy Cappa Biologics	
14:15	Encelta	
14:30	Break	
14:45	Arakena Pharmaceuticals	
15:00	HemostOD	
15:15	MT-act	
15:30	Seal Therapeutics	
15:45	Cellis	
16:00	Neurosterix	
16:15	Release Therapeutics	

Moderation: **Ximing Ding**, Investment Manager, & **Butrint Aliu**, Analyst, Pureos Bioventures

Clinical stage companies

Presented by **CELONIC**

Time	Company	Room Montreal
12:30	Celonic	
12:45	ArtBio	
13:00	FoRx Therapeutics	
13:15	RDP Pharma	
13:30	Vaccentis	
13:45	Anaveon	
14:00	Metriopharm	
14:15	AB2 Bio	
14:30	Break	
14:45	Azafaros	
15:00	Vaderis Therapeutics	
15:15	NovaGo Therapeutics	
15:30	Stalica	
15:45	Immunophotonics	
16:00	Quercis Pharma	
16:15	Molecular Partners	
16:30	Pharvaris	

Moderation: **Georg Blaser**, & **Thomas Francillette**, Celonic Group

Commercial stage companies

Time	Company	Room Osaka/Samarkand
12:30	Lonza	
12:45	Parexel	
13:00	Vetter Pharma	
13:15	DeepLife	
13:30	Advanced Clinical	
13:45	Valgenesis	
14:00	Aptar Pharma	
14:15	MSD	
14:30	Break	
14:45	KBI Biopharma	
15:00	ProtaGene	
15:15	Dinamiqs	
15:30	Sartorius Stedim	
15:45	Enzene	
16:00	Skyepharma	
16:15	Concept Life Sciences	
16:30	Light Chain Bioscience – Novimmune	

Moderation: **Marta Gehring**, Swiss Biotech Association

Panel discussion & pitching session

Presented by **SIEMENS**

12:15-13:00 Panel: Industrial biotech

MCH Lounge

Why take 10 years to launch a new biotech product when you can do it much faster?

Accelerating Biotech Innovation Through Digital Transformation: This panel explores how digital technologies can revolutionize the traditional 10-year biotech development cycle. Experts from startups, Big Pharma, and research discuss compression of time-to-market while maintaining quality and safety. Key topics include digital transformation, biotechnology innovations, physical-digital convergence, and sustainable approaches. The session showcases integrated solutions from lab automation to analytics that optimize the R&D-to-production lifecycle.

Moderation: **Jens Feddern**, Vertical Market Manager Life Sciences, Siemens Schweiz

Panelists:

Lutz Salomon, Technical Account Manager for Pharma, Siemens Schweiz

Further panelists can be found on our website

Presented by **wipro**

13:00-13:45 Panel 20

MCH Lounge

Driving R&D innovation using evolving technologies: Pragmatic perspectives

In an era where life sciences organizations are navigating an increasingly crowded landscape to bring complex therapies to market faster and more efficiently, innovation has become a necessity. Technologies such as AI/ML, and automation promise to revolutionize R&D, but successful utilization requires more than just technical capability. It demands a clear understanding of how to apply these technologies within operational and regulatory realities. Our panel brings together a diverse group of experts from across the ecosystem. The panelists will share their individual experiences and insights on balancing innovation and practicality to deliver solutions that are viable, scalable, and aligned with R&D objectives.

Moderation: **Dan White**, Chief Operating Officer, Wipro Lifesciences Solutions

Panelists:

Dinesh Kasthuril, VP, US Delivery and Strategy Head, Wipro Lifesciences Solutions

Further panelists can be found on our website

Panel discussions

Presented by **Schellenberg Wittmer**

14:00-14:45 Panel 24

MCH Lounge

Licensing with strategic partners

Intellectual property is a key driver of the enterprise value, and its licensing-in and -out is a business model in the life sciences industry. Licensing with strategic partners allows companies to strengthen product development, create synergies, and enter new markets. Experts from Swiss and international companies will discuss what needs to be considered when evaluating licensing strategies and what are the opportunities and challenges in the long term.

Moderation: **Lorenza Ferrari Hofer**, Partner, Schellenberg Wittmer

Panelists:

Peter Droc, Business Unit Head Drug Product Services, Lonza

Michael R. Hübner, Director, Country Lead EIP Switzerland, Johnson & Johnson Innovation

Michael Pitzner, General Counsel & Compliance Officer, SVP Legal and Business Development Molecular Partners

Presented by **zühlke**
shaping ideas

15:00-15:45 Panel 28

MCH Lounge

New challenges in biotech manufacturing and supply chain: How can AI help?

The biotech manufacturing sector is facing challenges to scale efficiently and maintain consistency. Failure to address these issues can lead to inconsistent product quality, regulatory setbacks, and limited patient access to critical therapies. New technologies such as AI-driven automation and flexible manufacturing platforms offer opportunities to enhance efficiency and resilience. Our panel will explore the transformative solutions shaping biotech manufacturing over the next three years.

Moderation: **Daniel Wilhelm**, Managing Director Health Industry Switzerland, Zühlke

Panelists:

Thibault Geoui, Thought Leader in Data & AI for the Pharma and Biotech Industry, Zühlke

Monitha Harlikumar, Director Data & Digital Acceleration Lead, Manufacturing / Pharma, F. Hoffmann-La Roche

Panel discussions

Presented by **NEW BIOLOGIX**

16:00-16:45 Panel 32

MCH Lounge

Looking to the future of gene therapy manufacturing

This dynamic panel unites gene therapy developers, biotech innovators, and manufacturing leaders to explore challenges in gene therapy production. Panelists will discuss bottlenecks, scalability, and regulatory hurdles while balancing innovation and cost-efficiency. The goal is to identify key risks and unmet needs to shape a high-yield, high-quality and safe production model, essential for expanding access to life-changing therapies worldwide.

Moderation: **Eduardo Ayuso**, CTO, SIEGFRIED DINAMIQS

Panelists:

Igor Fisch, CEO, NewBiologix

Markus Rüegg, CEO, SEAL Therapeutics

Harald Petry, CEO, Avrion Therapeutics

Doris Wrobe, Modality Head GT - Portfolio Management GT, Novartis

Find details about the panel discussions here →



Company presentations | panel discussions

Time	Company	Marriott Hotel room 1+2
12:30	Novigenix	
12:45	EyeOn The Netherlands	
13:00	Decisive Consulting	
13:15	Enamine	
13:30	Michalski • Hüttermann & Partner Patent Attorneys	

Moderation: **Richard Jarvis**

Presented by  **XDC**
The Biocoupling Leader

14:00-14:45 Panel 25

Marriott Hotel room 1+2

Licensing, partnerships and newco in the ADC space, and the critical role of CMC

The ADC industry is undergoing unprecedented growth, propelled by cutting-edge innovations and a wave of high-profile collaborations between multinational corporations (MNCs) and pioneering biotechs. Landmark deals (in USD) such as Pfizer's 43 billion acquisition of Seagen, AbbVie's 10 billion purchase of ImmunoGen, Genmab's 1.8 billion acquisition of the Chinese biotech ProfoundBio and Merck's potential 22 billion partnership with Daiichi Sankyo exemplify this trend, with investments surpassing 100 billion in partnerships and M&A since 2019. These alliances are accelerating the development of ADC therapies, blending scientific ingenuity with therapeutic promise. Yet, their success depends on robust chemistry, manufacturing, and controls (CMC) development, which ensures product quality, scalability, and regulatory compliance - critical pillars that transform innovative concepts into market-ready solutions. In this panel, we will examine how licensing, newco formation, and strategic partnerships are reshaping the ADC landscape and why high quality CMC is critical for the success of partnership deals during due diligence and post-deal product development.

Moderation: **Ulf Grawunder**, CEO, T-CURX

Panelists:

Dominik Schumacher, CEO, Tubulis

Jing Li, Founder & CEO, VelaVigo

Ying Wang Schmidt, Senior Director Corporate Business Development, Roche

Dominik Escher, Managing Partner, Pureos Bioventures

Jimmy Li, CEO, WuXi XDC

Panel discussions

Presented by  **MOLECULAR PARTNERS**

15:00-15:45 Panel 29

Marriott Hotel room 1+2

Radioligand therapies: Opportunities and challenges for Switzerland and globally

Please find all details on our website

Moderation: **Philippe Legenne**, CMO, Molecular Partners

Panelists:

Melpomeni Fani, Head of Radiopharmaceutical Chemistry, University Hospital Basel

Sibylle Jennings, Global Regulatory Team Lead, Radiosensitive Cancers, Novartis

Emanuele Ostuni, CEO, ARTBIO

Arnaud Lesegretain, CEO, Orano Med

Presented by  **SWISSMEDIC**

16:00-16:45 Panel 33

Marriott Hotel room 1+2

From innovation to patient: Swissmedic's role in accelerating drug development and patient access

This panel will explore the journey of a medication from early innovation to market authorization, highlighting Swissmedic's key support mechanisms. Topics include the Innovation Office, scientific advice for clinical trials, fast-track pathways for unmet patient needs, continuous engagement with developers, pipeline meetings, regulatory clarifications as well as international collaboration and harmonization to enhance patient access to innovative treatments.

Moderation: **Eliane Schmid**, Head of Communication, Swissmedic

Panelists:

Benoît Dubuis, President, Fondation INARTIS

Laura Andrea Wyss, Associate Director Regulatory Strategy, Moderna Switzerland

Sandra Zaugg, Head Division Regulatory Assessment, Swissmedic

Julia Djonova, Head Division ATMP, Swissmedic

Deana Mohr, co-Founder & CEO, MUVON Therapeutics

Panel discussions

Presented by  Swiss Biotech Association

12:15-13:00 Pitch 8: Diagnostics & lab automation chapter

Marriott Hotel room 3+4+5

Transformative startups in next-gen diagnostics & lab automation

Discover the future of biotech as startups push the boundaries of diagnostics, lab automation, analytics and drug discovery. This session will feature groundbreaking technologies transforming disease detection, laboratory sciences and the way therapies are developed. Presenters will explore innovations in single-particle dispensation, real-time immunoassays, VR-powered diagnostics, next-gen allergy testing, precision medicine driven by biomarker insights, solutions advancing light-dependent biological techniques and novel approaches to accelerating drug development. Join experts and investors as they explore how these technologies are reshaping the landscape of healthcare and biotech.

Moderation: **Samantha Paoletti**, Head of Research and BD Life Science Technologies, CSEM

Jury: **Bernard Spycher**, Board Member, SVDI | **Miro Venturi**, President, Diamante Healthcare Consulting | **Cédric Barra**, Senior Investment Manager Life Sciences, OCCIDENT | **Steffen Ehrhardt**, VP Investor Community, Partnerships and Sustainability, SICTIC

12:15 Introduction

12:20 OptoLumina

12:25 Bioscibex

12:30 SEED Biosciences

12:35 Atanis Biotech

12:40 Elionova

12:45 Xemperia

12:50 MachineMD

12:55 Voting and closing remarks

Panel discussions

Presented by   Swiss Biotech Association

13:00-13:45 Panel 21: Diagnostics & lab automation chapter

Marriott Hotel room 3+4+5

Diagnostics in focus: Enabling precision from discovery to monitoring

This year's panel explores the evolving role of diagnostics in advancing precision medicine — from discovery to real-world application. We'll examine how innovations in biomarker development, lab automation and data-driven diagnostics are transforming how we detect, characterize and monitor disease. The discussion will also address technologies enabling minimal residual disease (MRD) detection and recurrence monitoring, while reflecting on the broader convergence of diagnostics, informatics and therapeutic decision-making. With perspectives spanning assay development, clinical integration and enabling platforms, the panel offers a comprehensive view of where diagnostics is heading next.

Moderation: **Miro Venturi**, President, DIAMANTE Healthcare Consulting

Panelists:

Brian Hashemi, CEO, Novigenix

Luca Cicchetti, VP Commercial Executive, Bio-Techne

Carlo Maria Messina, VP Medical Affairs, EXACT Sciences

Presented by  **OBELYSQ**
CLINICAL QUALITY EXPERTISE

14:00-14:45 Panel 26

Marriott Hotel room 3+4+5

Effective quality management system for biotechs: The pragmatic approach

The panel explores how biotech companies can implement efficient, inspection-ready and compliance-driven quality management systems (QMS) without unnecessary complexity. Experts from regulatory, operational, and quality assurance will share insights on tailoring QMS, balancing compliance and agility, and avoiding common pitfalls. Attendees will gain actionable takeaways on risk-based approaches and best practices to build a robust yet flexible QMS.

Moderation: **Arnaud Levain Chavanon**, Managing Director, ObelysQ

Panelists:

Ludovic Moulin, Managing Director, ObelysQ

Clare Price, VP Clinical Operations, CDR-Life

Debora Schmitz-Rohmer, Head of Development, T3 Pharma

Kirsten Leidreiter, Head of Clinical Study Assessor, Swissmedic

Panel discussions

Presented by 

15:00-15:45 Panel 30

Marriott Hotel room 3+4+5

Raising a large VC round: Do's, don'ts, opportunities, risks and trends

Last year more than 10 Swiss biotechs and 50 European biotechs raised a financing round above USD 50 million. What did they do right, what did they have to commit to, and what could they share about the experience? As in previous years, we will again look at financing developments and trends and what this means for companies looking to raise money in 2025 and beyond. Join us to hear from a panel of VCs, CEOs and industry experts.

Moderation: **Peter Mozerov**, Senior Manager, KPMG

Panelists:

Patrik Frei, Founder and CEO, Venture Valuation

Tim Dyer, CEO, Neurosterix

Valentin Piëch, Managing Partner, BioMedVC

Andreas Wallnöfer, Serial Biotech Entrepreneur

Presented by  

16:00-16:45 Panel 34

Marriott Hotel room 3+4+5

Bridging continents: Navigating US funding for Swiss biotechs

This panel brings together key stakeholders from both sides of the Atlantic to explore the opportunities and challenges of securing US funding for Swiss biotech companies. Investors and representatives from Swiss biotechs will share their insights on the current landscape, discuss strategies for successful fundraising, and highlight the unique advantages and potential hurdles faced by Swiss firms in the US market.

Moderation: **Branden C. Berns**, Partner, Gibson, Dunn & Crutcher

Panelists:

Matthias Bodenstedt, CFO, MoonLake Immunotherapeutics

Nicolas Mosimann, Partner, Kellerhals Carrard

Melanie Rolli, Group CEO, Helsinn

Nate Chang, Operating Partner Life Sciences, Playground Global

Panel discussions

Presented by  

13:00-13:45 Panel 22

Room Rio

Brains helping brains and scientists funding scientists: Can decentralized science enhance the biotech funding landscape?

Decentralized funding and decentralized science are a powerful combination that is democratizing the funding and science aspects of the risky but sometimes rewarding investments in new medicines for unmet medical needs. While IP ownership is regulated in a classical manner, IP-NFTs (Non-fungible tokens) allow for limited licensing to buyers. Smart contracting through the blockchain adds to automation of transfer of ownership and licensing. Typically, IP-NFT token owners are also directly involved in the voting of projects. The latter has clear advantages over the traditional top-down decision-making in corporate structures.

Moderation: **Peter Groenen**, Head Translational Science / Consultant, Cerebrum DAO / Alpinuity Bio

Panelists:

Brian Magierski, Founding steward, serial entrepreneur, Cerebrum DAO

Sebastian Gensior, Founder, Slate Mountain Capital

Antonella Santucci Chadha, Founder, Chief Medical Officer, Board Member, Advisor, Women's Brain Foundation

Santosh Dixit, Chief Domain Expert (Healthcare and Life Sciences) Innovation Labs, Persistent Systems

Douglas Haggstrom, Lead, Antimicrobial Resistance & Life Sciences, Innovation Office University of Basel

Find details about the panel discussions here →



Panel discussions

Presented by 

14:00-14:45 Panel 27

Room Rio

Harnessing life science and NGO collaborations to drive social impact

Life Science Cares Switzerland (LSCS) connects the life sciences sector with local non-profits to empower disadvantaged kids and young adults in Switzerland. Join us for this panel discussion on collaborations between the life science community and local NGOs. Nadine Zahnd, Managing Director of LSCS, will share the organization's vision. Bill Burns, LSCS Ambassador, will explore the benefits for the life sciences community. Isabelle Dalli-Wyniger will examine corporate roles in philanthropy. Amanda Gogates will highlight the value of collaborations. Renate Gloggner will discuss volunteering's impact on employee satisfaction and how it helps turn corporate social responsibility into meaningful action. The session will be moderated by Patrick Amstutz, LSCS Founder.

Moderation: **Patrick Amstutz**, CEO, Molecular Partners, & President, Swiss Biotech Association

Panelists:

Bill Burns, Chair of the Board of Directors, Molecular Partners

Isabel Dalli-Wyniger, Head Global Philanthropy and Donations, Novartis

Renate Gloggner, EVP People and Community, Molecular Partners

Amanda Gogates, Managing Director, Wyss Zurich

Nadine Zahnd, CEO, Life Science Cares Switzerland

Presented by  Swiss Biotech Association

15:00-15:45 Panel 31

Room Rio

Swiss Biotech Association – Legal Chapter, boosting your exit: Sale, IPO, licensing

Please find all details on our website

Moderation: **Dieter Gericke**, Partner, Homburger

Panelists:

Fabian Meyer, Partner, EY

Matthias Staehelin, Partner, VISCHER

Maurus Winzap, Partner, WalderWyss

Panel discussions

Presented by  Global Village

12:00-12:45 Joint panel session

Verseau

Bridging borders: Strategies in global partnering and deal making for biotech

Join us for a dynamic panel exploring the nuances and strategies of cross-border partnering and deal making in the life sciences sector. This panel brings together seasoned investors and business development leaders from around the globe to share insights on sourcing opportunities, structuring international deals, and forging strategic partnerships across markets.

We'll explore the nuances of working across geographies and highlight what it takes to create value through cross-border collaboration. Whether you're an investor, dealmaker, or business development executive, this session offers real-world perspectives on building successful global relationships in a rapidly evolving landscape.

Moderation: **Lorenzo Leoni**, Managing Partner, TiVentures

Panelists:

Karen Wagner, General Partner, Ysios Capital

Hanns-Georg Klein, Founder, Acmaias

Nate Change, Operating Partner Life Sciences, Playground Global

Sivadasan Krishnan, VP Search & Evaluation – Research & Technologies, Global Business Development Daiichi Sankyo

Presented by 

13:00-13:45 Panel 23

Verseau

I can't take my eyes off you: Swiss innovation and why it attracts international investors

We talk about the Swiss innovation and how attractive it is for international investors and will hear the perspectives of an international VC investor, a Swiss incubator, and a biotech executive.

Moderation: **Gabriela Ecco**, Principal, +ND Capital | **Elena Battistello**, Analyst, Novartis Venture Fund

Panelists:

Daniela Couto, General Partner, BioGeneration Ventures

Virginia Ballotta, Manager New Ventures, BaseLaunch

Klaus Dugi, CEO, Vandria

Floor map

This year's Swiss Biotech Day is taking place at the Congress Center Basel and the Eventhall. This venue overview will help you navigate the space and locate key areas during the conference. Detailed floor plans are on the following pages.




Scan the QR code to access the interactive floor plan, where you can easily locate session rooms, partnering areas, and exhibitor booths. To find an exhibitor's exact location and company information, select a booth number or exhibitor name. You can also explore the partnering, panel, and pitching areas for more details.

Not sure where to go? Just ask our friendly staff in the green 'Ask Me' T-shirts.


Floor map



Level 3
Congress Center



Level 2
Congress Center



Level 1
Congress Center
& Marriott Hotel



Level 0
Eventhall

- Exhibitor booth
- Mentoring booth
- Swiss cluster booth
- Global village
- Catering
- Coffee bike
- Media table
- Poster exhibition
- Partnering areas
- Lounge area


Floor map

Level 0 | Eventhall




Floor map

Level 1 | Eventhall • Gallery



Floor map


Level 2 | Congress Center



- Exhibitor booth
- Mentoring booth
- Swiss cluster booth
- Global village
- Catering
- Coffee bike
- Media table
- Poster exhibition
- Partnering areas
- Lounge area

Floor map

Level 3 | Congress Center



Overview of conference rooms		
Name	Level	Program
MCH Lounge	0	Panels
Verseau	0	Global Village stream
Marriott 1+2	1	Panels Commercial stage company presentations
Marriott 4+5+6	1	Panels Pitches
Montreal	2	Plenary sessions Clinical stage company pres. Panel
Singapore	2	Emerging company presentations Pitches
Rio	2	Panels Pitches
Osaka/Samarkand	3	Commercial stage company presentations

Exhibitors | level 2, Congress Center

Booth	Exhibitor
#1	Swiss Biotech Association 
#2	Friends of the Swiss Biotech Association    
#3	Pulse by EPIC Suisse 
#4	Biopôle 
#5	Experimental Pharmacology & Oncology 
#6	R&G Pharma Studies 
#7	BIOIVT 
#8	PMI Science 
#8a	ICOSAGEN 
#9	Plasmid Factory 
#10	PolyPeptide Group 
#11	Aldevron 
#12	Comac Medical 
#13	Sino Biological 
#14	PSI CRO 
#15	Pharmaron 
#16	Carbogen 
#17	Luminance Health 
#18	Scienion 
#19	Superlab Suisse 

Exhibitors | level 2, Congress Center

Booth	Exhibitor
#20	Selvita 
#21	SAKK Coordinating Center 
#22	Symbiosis 
#23	Hamilton 
#24	CROss Alliance® 
#25	CRB Group 
#26	SGS Vitrology 
#27	SGS Analytics Switzerland 
#28	YUMAB 
#29	KLIFO 
#30	KBI Biopharma 
#31	Crown Bioscience 
#32	WuXi AppTec 
#33	Ardena Holding 
#34	Citeline 
#35	Almac Group 
#36	Cytiva 
#37	Quality Assistance 
#38	LubioScience 
#39	Nikon 

Exhibitors | level 2, Congress Center

Booth	Exhibitor	
#40	MediTox	
#41	CSL Behring	
#42	Allucent	
#43	Tigermед	
#44	Eurofins CDMO	
#45	Clinigen Group	
#46	ObelysQ	
#47	Miltenyi Biotec	
#48	Mettler Toledo	
#49	BioConcept	
#50	Parexel	
#51	Microsynth	
#52	ProtaGene	
#53	MLM Medical Labs	
#54	Worldwide Clinical Trials	
#55	CSEM	
#56	Hoffmann & Partner	
#57	MyData-TRUST	
#58	Medicilon	
#59	Wacker Chemie	
#60	Pharmadule Morimatsu	

Exhibitors | level 0, Eventhall

Booth	Exhibitor	
#61	Altascience	
#62	Schedio	
#63	Dinamiqs	
#64	Grand train tour of Switzerland	
#65	PSM	
#66	Labcorp	
#67	LYO-X	
#68	ZETA	
#69	Wemedoo	
#70	Diatheva	
#71	Biosynth	
#72	Latvian Institute of Organic Synthesis	
#73	Valgenesis	
#74	JACOBS	
#75	BIOINTRON	
#76	Cube Biotech	
#77	Wipro	
#78	cellab	
#79	Brand Institute	
#80	Idexx	
#81	Celonic	

Exhibitors | level 0, Eventhall

Booth	Exhibitor	
#82	Gerresheimer	
#83	WuXi XDC	
#84	Biotech Innovation Procurement Platform	
#85	Accelsiors	
#86	PHT Pharmaceutical	
#87	BIO4	
#88	Bio-Techne	
#89	CRS Clinical Research Services Mannheim	
#90	DHL Express	
#91	ten23 health	
#92	Menarini Biotech	
#93	ERBC Group	
#94	Asymchem Laboratories	
#95	Vetter Pharma-Fertigung	
#96	Pharmabotix	
#97	GENEWIZ from Azenta Life Sciences	
#98	Prasfarma	
#99	Capricorn	
#100	PharmaLex Healthcare	
#101	Sartorius Stedim	

Exhibitors | level 0, Eventhall

Booth	Exhibitor	
#102	Guidance	
#103	GenomeScan	
#104	Octapharma	
#105	AcroBiosystems	
#106	Citibank	
#107	Richmond Pharmacology	
#108	Integra	
#109	A&M Labor für Analytik und Metabolismusforschung	
#110	LI-COR Biosciences	
#111	Aliri Bioanalysis	
#112	Fortrea	
#113	Medscape	
#114	Swiss Biotech Association	

Find further information about the exhibitors here →



Mentoring booths | level 0, Eventhall

The mentoring booths offer personalized guidance by specializing in topics relevant to biotech CEOs across the entire value chain.

Booth	Exhibitor
#MB1	Commercial partnerships & market access Farmamondo 
#MB2	Market access, HTA & pricing HealthEcon 
#MB3	Where innovation meets regulation Swissmedic 
#MB4	Capital market access SIX Swiss Exchange & Stifel 
#MB5	Non-dilutive including European funding Euresearch & Innosuisse 
#MB6	International expansion and export Switzerland Global Enterprise 
#MB6a	Legal, tax & accounting Swiss Biotech Association Chapter 
#MB7	Clinical development Advanced Clinical Switzerland 

Swiss cluster booths | level 0, Eventhall

The Swiss cluster booths exhibit the innovation power of Switzerland. Selected clusters offer insight into their activities and are interested in exploring collaboration opportunities.

Booth	Exhibitor
#SC1	Valais Cluster (BioArk) 
#SC2	USI (Università della Svizzera italiana) 
#SC3	Balgrist Campus 
#SC4	Biotechnet 
#SC5	Life Science Cares 
#SC6	Horgen Labs 
#SC7	Wyss Center Geneva 
#SC8	Venture 
#SC9	Organ-on-a-chip 
#SC10	Non-animal methods in R&D 

Poster presentation

No.	Company	Level
#1	Abbmira Therapeutics	0
#2	ACM Biosciences	0
#3	Adoram Therapeutics	0
#4	Adularia	0
#5	AlphaMol	0
#6	Altamira Therapeutics	0
#7	AlveoliX	0
#8	Amphasys	0
#9	Amphilix	0
#10	Amporin Pharmaceuticals	0
#11	AMYRA	0
#12	ARTBIO Biotech	0
#13	Aurealis Therapeutics	0
#14	AVRION Therapeutics	0
#15	AxCellerate	0
#16	Azafaros	0
#17	BigOmics	0
#18	CELLnTEC	0
#19	ClexBio	2
#20	dEEGtal	2
#21	DINAMIQS	2
#22	Elionova	2
#23	Enantios	2
#24	Encelta	2
#25	EsoCap	2
#26	eviive	2
#27	FluoSphera	2
#28	FoRx Therapeutics	2
#29	GlycoEra	2
#30	IBEX Therapeutics	2
#31	Inhalis Therapeutics	2
#32	InkVivo	2
#33	inSEIT	2
#34	InSphero	2
#35	IONctura	2
#36	Juvion Health Sciences	2
#37	Legacy Healthcare	2
#38	Limula	2
#39	Mabylon	2
#40	MedScienceSwiss	2

Poster presentation


No.	Company	Level
#41	Memo Therapeutics	2
#42	MetrioPharm	2
#43	MPC Therapeutics	2
#44	MV BioTherapeutics	2
#45	Nagi Bioscience	2
#46	Neurosterix	2
#47	Nexco Onex	2
#48	Nouscom	2
#49	Novigenix	2
#50	Novochizol	2
#51	ONtrack	2
#52	Onward Therapeutics	2
#53	OptoLumina	2
#54	Oryl Photonics	2
#55	PDC Therapeutics	2
#56	Perseo Pharma	2
#57	Pilatus Biosciences	3
#58	Polaroid Therapeutics	3
#59	Procavea Biotech	3
#60	Prometheus	3
#61	Quant Biomarkers	3
#62	Release Therapeutics	3
#63	Renaldee	3
#64	Selmod	3
#65	Somagenetix	3
#66	SunRegen Healthcare	3
#67	Synendos Therapeutics	3
#68	T-Oncology	3
#69	ten23	3
#70	TheraPPI	3
#71	TissueLabs	3
#72	Topadur	3
#73	Torqur	3
#74	Vaderis Therapeutics	3
#75	Versameb	3
#76	Volv	3
#77	Xemperia	3
#78	Xenometrix	3
#79	Ymmunobio	3
#80	YONISolutions	3

Poster presentation



No.	Biotechnet platform	Place
BTN 1	Antibiotics	Swiss Cluster, level 0
BTN 2	Biomanufacturing	Swiss Cluster, level 0
BTN 3	Data science	Swiss Cluster, level 0
BTN 4	Stem cell research & regenerative medicine	Swiss Cluster, level 0
BTN 5	Tissue engineering for drug development	Swiss Cluster, level 0
BTN 6	In vitro diagnostics	Swiss Cluster, level 0

Where to find the posters:

Level 0, Reception south entrance & Eventhall



Poster presentation



Dedicated poster sessions:

- Monday, May 5, 14:00 - 14:45
- Tuesday, May 6, 12:00 - 12:45

Participating companies

(as of 22 April 2025) Member of the Swiss Biotech Association

Company	Country
ILEVA Sciences GmbH	DE
[i]to Business Intelligence	DE
+ND Capital	CH
1MED SA	CH
2 Bridge nv	BE
3i	CH
3T Biosciences Europe GmbH	CH
4Bases SA	CH
4BIO Partners LLP	UK
4TEEN4 Pharmaceuticals GmbH	DE
7AlpsBio GmbH	CH
A&M Laboratory Group	DE
AAA Family Office	IL
AAtec Medical GmbH	DE
AAVATAR Therapeutics	KR
AB2 Bio Ltd	CH
AbbmiraTherapeuticsAG	CH
AbbVie	DE
abc biopoly ag	CH
abcDNA GmbH	CH
ABF Pharmaceutical Services GmbH	AT
Aboligix Sàrl	CH
Abrinca Genomics	CH
Abzena	UK
Accelagen	AU
Accelera S.r.l.	IT
Accelsiors AG	CH
Achelous Partners	NL
Acies Bio d.o.o.	SI
Acino International Ltd	CH
ACROBiosystems	CH
ACTIV-H	FR
Adalid Sciences	CZ
Adámas Nanotechnologies, Inc.	US
Adamastor Bioservices Srl	IT
ADARE PHARMACEUTICALS SRL	IT
Adecco Humaines Ressources SA	CH
adesso Schweiz AG	CH
Adiposs SA	CH
Aditum Bio	US
ADMEDDICON - DMPK Consulting	DE
admedicum GmbH & Co KG	DE
Adolf Kühner AG	CH
Adoram Therapeutics SA	CH

Company	Country
Adryan AG	CH
Advanced Clinical GmbH	DE
ADVAXIA BIOLOGICS	IT
Advestra AG	CH
AESARA, Inc.	US
AGATHA	FR
AGC Biologics	DK
AGC Pharma Chemicals Europe, S.L.U.	ES
Agility Life Sciences	UK
AIPTO TechBio GmbH	CH
AIT STUDIO Co.Ltd	KR
akampion	DE
Akceso Advisors AG	CH
AKKODIS	CH / ES
Akylux Therapeutics	CH
ALCURA	UK / ES
Aldevron	US
Alentis Therapeutics AG	CH
Aleon Pharma International, Inc	US
Aleos Bio	CH
Alga Biologics	FR
Alhena Consult	FR
Alira Health	DE / IT / ES
Alira Health AG	CH
Aliri Bioanalysis	US
AlivaMab Biologics, LLC	US
Alkapharmics SARL	CH
Allegria Therapeutics AG	CH
Alltim GmbH	CH
Allucent	US
Almac Group	UK
AlphaMol Science AG	CH
AlphaOnco Swiss SA	CH
Alpinity Bio GmbH	CH
ARTEFACT Therapeutics AG	CH
Altasciences	CA
Alterbiotix	CH
AlveoliX AG	CH
AM-Pharma	NL
AMAL THERAPEUTICS SA	CH
Ambiotis	FR
Amphasys AG	CH
AmphiliX AG	CH
Ampleia	FR

Participating companies

Company	Country
Amporin Pharmaceuticals AG	CH
Ampure Srl.	IT
AMR Action Fund	CH
Amt für Wirtschaft und Arbeit Basel-Stadt	CH
Amyl Therapeutics SRL	BE
AMYRA Biotech AG	CH
Analytik Jena GmbH+Co. KG	DE
AnaPath Services GmbH	CH
Anapharm Bioanalytics	ES
Anaveon AG	CH
ANPOLY	KR
ANSEA AG	CH
ANTABIO SAS	FR
anteris helvetia AG - Kymanox Europe	CH
Antion Biosciences	CH
Apellis International GmbH	CH
APELOA	CN / DE
Aphaia Pharma AG	CH
Apollo Hospitals Educational and Research Foundation (AHERF)	IN
Apollo Ventures Holding GmbH	DE
APR Applied Pharma Research S.A.	CH
Aptar Pharma	FR
Araceli Biosciences	US
Aragen	US
Arakena Pharmaceuticals GmbH	CH
Araris Biotech AG	CH
Ardena Holding NV	BE
ARENSIA EXPLORATORY MEDICINE	DE
Aretè Solutions Sagl	CH
Argentum Consultants	IL
Arithmos Tech	UK
Arphamid Therapeutics GmbH	CH
ArtBio GmbH	CH
ARTEFACT	CH
ARTIC Technologies B.V.	NL
Asahi Kasei Pharma	JP / US / DE
ASGENTO	DE
ASKA Pharmaceutical Co., Ltd.	UK
Asklepios Advisors	CH
Asociación Española de BioEmpresas	ES
Aspeya	CH
assay.works GmbH	DE
Association BioAlps	CH

Company	Country
Association Life Sciences Competence Center (LSCC)	CH
ASTAT	GR
Astellas	UK
Astra Zeneca	CH
Astrum	DE
Asymchem Laboratories (Tianjin) Co., Ltd	CN
Athebio AG	CH
ATLANTIC BONE SCREEN	FR
Atopia Therapeutics	CH
Aukera Therapeutics GmbH	CH
Aurealis Therapeutics AG	CH
Aurigon GmbH	DE
Aurilide Ltd	FI
Australian Embassy	CH
Austrian Business Agency GmbH	AT
Auxenion Research AG	CH
Avance Basel GmbH	CH
AVEctivate GmbH	CH
Avenza Consulting Sàrl	CH
Averen, pharmaceutical consulting	DE
Avrion Therapeutics	CH
AWS (Amazon Web Services)	CH
Axcelerate Drug Discovery Partners, Inc.	JP
AxCellerate Sagl	CH
axcura AG	CH
AXFEN BIO	FR
Axxam SpA	IT
Azafaros Switzerland AG	CH
Azma Polymer Radin Shiraz	IR
B SQUARED Sarl	CH
Baccinex SA	CH
Bachem AG	CH
Baden-Württemberg International GmbH	DE
BAG Health Care GmbH	DE
Baker McKenzie	UK / US
Baker McKenzie AG	CH
Balgrist Campus AG	CH
Baliopharm AG	CH
bamconn GmbH	DE
Bank of America	DE
Bär & Karrer AG Basel	CH
Barrington James	UK
Basel Area Business & Innovation	CH

Participating companies

Company	Country
Basel Pharma Networking Group	CH / FR
BaselLaunch	CH
BASQUE HEALTH CLUSTER	ES
Bavarian Nordic Berna GmbH	CH
Baxiva AG	CH
BBD BioPhenix SLU - Biobide	ES
Becton Dickinson AG	CH
BeCytes Biotechnologies	ES
BeiGene	CH
Beijing Dachao Biotechnology Co., Ltd.	CN
Belach Bioteknik AB	SE
Berlin Innovation Ventures GmbH	DE
Bern Economic Development Agency	CH
BERNINA BioInvest AG	CH
bespark*bio	AT
BespokExe sarl	CH
BEYOND GENOMIX SA	CH
BGV	NL
BigOmics Analytics SA	CH
Bimini Biotech	NL
BIMOVIS GmbH	DE
Bio-Rad Laboratories AG	CH
Bio-Technopark Schlieren-Zürich	CH
BIO4 LTD Belgrade	RS
BioAgilytix GmbH	DE
Bioark SA	CH
BioAscent Discovery Limited	UK
BioConcept AG	CH
BioConfidant Sàrl	CH
BioConnection B.V.	NL
BioCopy AG	CH
Biocytogen Pharmaceuticals Beijing	CN
BioDecision Analytics Ltda	BR
BioDlink BioPharmCo. Ltd	CN
Bioengineering AG	CH
Biofactory Competence Center	CH
BioFi	CH
Biofidus AG	DE
Bioga	ES
Biogen International GmbH	CH
BIOGENERA SpA	IT
BioGenes GmbH	DE
Biointron	US
BioVT	US

Company	Country
Biolacuna Ltd	UK
BioLingus	CH
BioLizard SA	CH
Biolytix AG	CH
BioM Biotech Cluster Development GmbH	DE
BioMed X GmbH	DE
BioMedica	DE
Biomedical Translation Research Center (BioTReC), Academia Sinica	TW
BiomedVC AG	CH
biomindz	DE
Biopôle SA	CH
Bioprocess-Consulting	DE
BioRN Network e.V.	DE
Bioscibex SA	CH
BIOSPHERE SRL	IT
Biosynth	CH
Biotech Booster	NL
Biotech Ventures Advisory Group Sagl	CH
Biotechnet Switzerland	CH
BIOTECHNICA DWC LLC	DZ
BiotechTV	US
BiotechTx - Dr. Helene Chery-Hernandez	DE
Biotem	FR
Biotrial International Ltd	UK
BIOVECTRA Inc.	CA
BioVersys AG	CH
BioXconomy	UK
BioXpress Therapeutics SA	CH
BiProMicro	DE
BlackRock	CH
Blow S.L.	ES
blisc - bihlmann life science communication	CH
Blue Wave Therapeutics GmbH	CH
Bluepharma	PT
BMD Life Sciences GmbH	DE
Boehler Life Science Advice	CH
Bonetti & Partner GmbH	CH
BPNG	CH
BRAIN Biotech AG	DE
Brainlike Estratégia Regulatória Ltda	BR
Bramble Bio	PL
Brand Institute	US
Braunpat AG	CH

Participating companies

Company	Country
Brenntag Holding GmbH	DE
Bright Peak Therapeutics AG	CH
British Embassy Berne	CH
Bucher Biotec AG	CH
Bühlmann Laboratories AG	CH
Business & Economic Development, Canton Zurich	CH
Business Finland	DE
C&F EMEA GmbH	DE
CAI (Commissioning Agents International Suisse SA)	CH
Calida Therapeutics SAS	FR
Cambrex Corporation	US / SE
Campus Technologies Freiburg	DE
Canton Biologics Co., Ltd.	CN
CanVirex AG	CH
Capricorn Scientific GmbH	DE
Carbogen Amcis AG	CH
Careforce Switzerland AG	CH
Caron scientific	UK
Casebase Health	CH
Catalent	UK / BE / DE
Catalent Pharma Solutions GmbH	CH
Catalonia Trade & Investment	DE
Catalya SRL	BE
Catalyze BV	NL
Catenion GmbH	DE
CatSci Holdings Limited	UK
Cavenagh Health	CH
CBRE GWS	CH
CD4 Therapeutics GmbH	DE
CDBMCo	FR
CDR-Life AG	CH
CEBIS International	CH
Cedrus Group	CN
Cefriel S.c.r.l	IT
CEIBS Switzerland AG	CH
Celentyx Ltd	UK
Celerion Switzerland AG	CH
Celex Oncology Innovations Limited	UK
CELL-EASY	FR
CELLAB CDMO	AD
Cellbox Solutions	DE
Collectricon AB	SE
Cellestia Biotech AG	CH

Company	Country
Cellis	CH
CELLnTEC Advanced Cell Systems	CH
Cellula Therapeutics SA	CH
Cellvax SAS	FR
cellvie AG	CH
CellX Biosolutions AG	CH
Celonic AG	CH
Centerview Partners	UK
CER Groupe	BE
Cerbios-Pharma SA	CH
CERN	CH
Certara	DE
Cetacea Clinical GmbH	CH
chAlron SA	CH
Changchun GeneScience Pharmaceutical Co., Ltd	CN
Charles River Laboratories	US / DE / FR
CheckOrphan	CH
ChemBioFrance - CNRS	FR
ChemCon GmbH	DE
Chemengineering Switzerland AG	CH
CHEPLAPHARM Schweiz GmbH	FR
Children's Tumor Foundation Europe	BE
chimera biotec GmbH	DE
ChiroBlock GmbH	DE
ChromaCon AG	CH
CIC bioGUNE	ES
Cilatus Biopharma Consulting AG	CH
Cilcare	FR
Cimeio Therapeutics AG	CH
CinnaGen Co.	IR
CIS Biopharma AG	CH
Cisema	CN
Citeline	UK
Citibank	UK / DE
Citibank, N.A., Sioux Falls, Zurich Branch	CH
CK QLS	CH
Clarivate	UK
CLEAN CELLS	FR
Cleara Biotech	NL
ClexBio AG	CH
ClexBio AG	NO
ClinBAY ltd	CY
Clinexel Life Sciences Pvt Ltd	IN
Clinigen	UK

Participating companies

Company	Country
Clinigen Healthcare Switzerland SARL	CH
CliniSciences	FR
ClinOps Advisory Turner GmbH	CH
CMC & More GmbH	CH
Codetta Bio Inc.	US
Comac Medical	BG
Competitive Drug Development International Ltd	UK
Complyomics Sarl	CH
Concept Life Sciences	UK
Conscience	CA
CONVEYXO	BE
Cooley LLP	US / UK
Cor.Sync	BR
Corden Pharma	CH / DE / FR
Corning	NL
Coulter Partners	CH
Coulter Partnership srl	IT
Covington & Burling	UK
CPC Scientific	US
CRB Group GmbH	CH
CRITICA Pharmaceuticals PC	GR
CROSS Research SA - CROSS Alliance	CH
Crossroads Consultancy & Services	NL
Crown Bioscience	DE / NL
CRS Clinical Research Services Mannheim GmbH	DE
CRST (part of Link Medical)	FI
Crux Biolabs	AU
CSEM	CH
CSL	CH
CSL Vifor	CH
CTC Resourcing Solutions AG	CH
Cube Biotech GmbH	DE
Curare Swiss AG	CH
Curatis AG	CH
Cure Pharma (Switzerland) GmbH	CH
Curie.Bio	US
Cutempa Medical AG	CH
Cybiome GmbH	CH
Cyprotex	DE
Cytel	SE
Cytiva Europe GmbH	DE
Cytosurge AG	CH
CZ Vaccines	ES
dabl Clinical Trials	IE

Company	Country
Dachao Biotechnology Co., Ltd	CN
Daiichi Sankyo	JP / US / DE
Dalriada Drug Discovery	CA
DATAN Analytics GmbH	DE
Datasite	CH
DATWYLER PHARMA PACKAGING ITALY SRL	IT
DayOne	CH
DCZ Executive Search GmbH	DE
De Bord International Ltd.	CH
Debiopharm International SA	CH
Decisive Consulting Ltd	UK
Decomposition	KR
dEEGtal Insights SA	CH
Deep Tech Nation Switzerland Foundation	CH
DeepLife	FR
Deepson Bio	KR
Delin Ventures Ltd	UK
Deloitte AG	CH
Demcon Life Sciences & Health Eindhoven B.V.	NL
Department of Economic Affairs Canton of Zug	CH
Dermaliq Therapeutics GmbH	DE
Desire Ventures Inc.	CA
DeuterOncology	BE
Development Center for Biotechnology	TW
Dextronix	US
DFE Pharma	DE
DIAMANTE Healthcare Consulting	CH
Diatheva S.r.l.	IT
DICE CRO	BE
digitalswitzerland	CH
Dimericon Therapeutics AG	CH
DINABIOS AG	CH
Discovera S.r.l.	IT
DIVERCHIM CDMO	FR
DLR Projekträger	DE
DLRC Ltd.	UK
DNAi s.r.o.	CZ
DNTOX GmbH	DE
Dotlikon Exclusive Synthesis AG	CH
Dr Lang Consulting GmbH	DE
Dr. Schneider Partnerschaft	DE
Droia NV	BE
Drossapharm AG	CH
dsm-firmenich	CH

Participating companies

Company	Country
Dutch Embassy Bern	CH
DyoDelta Biosciences Ltd	UK
e-Proteins	BE
EA Pharma Co., Ltd.	JP
EBD Group GmbH	DE
Economic Development Partnership of North Carolina (EDPNC)	US
Economic Promotion Valais	CH
EDELRIE	FR
EdgeOne Venture Partners	US
Edmonton Global	CA
EMRx Pharmaceuticals SA	CH
EIT Health Germany-Switzerland CLC GmbH	DE
Eleks Holding OU	EE
eleva GmbH	DE
Eli Lilly (Suisse) SA	CH
Elionova AG	CH
Elix International SA	CH
Elixion Bio	CH
ELPRO AG	CH
Elthera AG	CH
EMBARGOMEDIA	KR
Embassy of Canada to Switzerland and Liechtenstein	CH
Embion Technologies SA	CH
Emtex AG	CH
Enable Biotech AG	CH
Enamine	UA
Enantios AG	CH
Encelta AG	CH
enGenes Biotech GmbH	AT
Enterprise Estonia	EE
Enterprise Ireland	DE
Entourage Pharma Consulting AG	CH
Enzene Inc.	US / LI
EPFL	CH
EPO Experimental Pharmacology and Oncology Berlin Buch	DE
EQT Life Sciences	NL
Equashield - Aagato Medical	BE
Equine Biotech	IN
EraCal Therapeutics Ltd	CH
ERBC	FR
Ernst & Young AG	CH

Company	Country
EsoCap AG	CH
Estetra SRL	BE
Estonian Chamber of Commerce in Switzerland	CH
Estonian Embassy Switzerland	EE
Estonian Ministry of Foreign Affairs	EE
ETH Zurich	CH
Ethris GmbH	DE
Euraxi Pharma	FR
Eureka Network Secretariat	BE
Euresearch	CH
Eurofins AMDE BIOANALYSES	FR
Eurofins BioPharma Product Testing Switzerland AG	CH
Eurofins CDMO	FR
Eurofins Discovery Services	FR
Eurofins Optimed	FR
Eurofins Professional Scientific Services AG	CH
Eurogentec	BE
EUROMED PHARMA SRL	IT
European Centre for Clinical Research Training	BE
EuroscreenFast	BE
Evercot AI GmbH	DE
EVERSANA Life Science Services LLC	US
EVIVE AG	CH
Evitria AG	CH
Evotec SE	DE
ExcellGene SA	CH
Excellis Europe Ltd. / NNIT Smart Supply Chain	UK
Exeris SA	CH
Exo Lab Italia Srl.	IT
ExperTrials	FR
Eyebright Medical Technology (Beijing) Co., Ltd.	CN
EyeOn	CH
F. Hoffmann-La Roche AG	CH
FarmaMondo Group SA	CH
FatAbGen International GmbH	CH
FB Global Regulatory Consulting and Coaching	CH
Ferring Pharmaceuticals A/S Soundport	DK
FGK Clinical Research GmbH	DE
FHNW	CH
Fidia Pharma (Switzerland) SA	CH
FimmCyte AG	CH
Finanz und Wirtschaft / Tamedia	CH
Fingerprint Group	CH

Participating companies

Company	Country
Fischer PreclinTox Consulting	CH
Flanders Investment & Trade Zurich	CH
Flex Databases s.r.o	CZ
Floratek Pharma SA	CH
FluoSphera SA	CH
Foley & Lardner LLP	US
Fondation Campus Biotech Geneva	CH
Fondation Inartis	CH
Fondazione Agire	CH
FONDAZIONE HUB INNOVAZIONE TRENINO	IT
Fongit - W Life Sciences	CH
Forbion	NL
Fördergesellschaft IZB mbH	DE
Fortrea	US / UK / DE
Fortrea Switzerland AG	CH
Forty51 Advisors AG	CH
Forvis Mazars SA	CH
Foundation Immune Engineering for Global Child and Adolescent Health	CH
Foundation Pestalozzi Schulcamps	CH
Fraunhofer IZI	DE
Fribourg Development Agency	CH
Frontage Laboratories	US / CN
FUJIFILM Co., Ltd.	JP
Fy Cappa Biologics	CH
FyoniBio GmbH	DE
G-Med Consulting Ltd.	CN
GalChimia, S.A.	ES
Galsler SA	CH
Galvita AG	CH
Ganda Business Solutions AG	CH
Gator Bio	CH
GBA Pharma GmbH	DE
gdhub	CH
Gearbox Biosciences	EE
Geberit RUF Stiftung	CH
GenCC GmbH & Co. KG	DE
Genechron Srl	IT
Genenta Science SpA	IT
Genentech Inc	US
Genesis Healthcare Co.	JP
Genesupport SA	CH
GeNeuro SA	CH
Geneva Business School	CH

Company	Country
Genevant Sciences GmbH	CH
Genewiz from Azenta Life Sciences	DE
Genioo AG	CH
Genius Search GmbH & Co. KG	DE
GENKO	BE
Gennaker BV	NL
GenomeScan B.V.	NL
GenScript Biotech (Netherlands) B.V.	NL
GenSearch Switzerland	CH
GenXBioscience AG	CH
Gerresheimer AG	DE
GHF Golden Heart Flower LTD	IL
Gibson, Dunn & Crutcher LLP	US
Gimv NV	BE
GIO Therapeutics AG	CH
Glatt Pharmaceutical Services GmbH & Co. KG	DE
GliaPharm SA	CH
GlioCART	CH
Global Clinical Trials LLC	US
GLOBALBIOTEC DIAGNOSTICS, S.L.	ES
GlycoEra AG	CH
GlycoThera Analytics GmbH	DE
GMP Bridge	ES
GMP-Verlag Peither	DE
Gouya Insights	AT
Grand River Aseptic Manufacturing	US
Greater Geneva Bern area	CH
GRIP Pharma	CH
Grund Intellectual Property Group	DE
Grünwald GmbH	DE
GTP Bioways CDMO	FR
Guangdong Raffles PharmaTech Co., Ltd.	CN
Gubra	DK
Guidance Tamil Nadu	IN
GXP Engaged Auditing Services GmbH	DE
HAMILTON BONADUZ AG	CH
Handelskammer Deutschland-Schweiz, AHK Schweiz	CH
Hangzhou Tigermed Consulting Co.,Ltd	CN
Harbor Bio Caelum Bio Stealth Biotech	CH
HAS Healthcare Advanced Synthesis SA	CH
Haya Therapeutics SA	CH
Hays (Schweiz) AG	CH
HBM Partners AG	CH

Participating companies

Company	Country
HdB-Law	CH
Healiva SA	CH
Health 2030 Genome Center	CH
Health Advances GmbH	CH
Health-Holland	NL
HealthCare Royalty	US
Healthecon AG	CH
HealthiBuddy Co., Ltd.	KR
Heidelberg Pharma AG	DE
Heidrick & Struggles	CH
HekeTiss SA	CH
Helbling Technik AG	CH
Hellenic Biocluster	GR
Helmes AS	EE
Helsinn Healthcare SA	CH
Hemetron AG	CH
HemostOD SA	CH
HES-SO Valais-Wallis	CH
Hippocrates Research Srl	IT
HKBio - Hong Kong Biotechnology Organization	CN
Hlx Life Sciences	CH
Hoffmann & Partner AG	CH
Homburger AG	CH
Hong Kong Shenzhen Innovation and Technology Park	CN
House of Lab Science AG	CH
HTCR-Services GmbH	DE
Huiyu Pharmaceutical Co., Ltd	CN
HUMANA BIOSCIENCES S.A.S.	FR
HungaroTrial Zrt.	HU
HWI pharma services GmbH	DE
Hydrogen group	UK
IBA Lifesciences GmbH	DE
IBMC CNRS	FR
IBR Inc., Institute for Biopharmaceutical Research	CH
ICEX	ES
Icosagen Cell Factory OÜ	EE
ICROM SRL	IT
iCure	CH
IDEXX BioAnalytics	DE
Idiomatic Bio	DK
Idorsia Pharmaceuticals Ltd.	CH
Igyxos	FR
Iktos	FR

Company	Country
ILIAS Biologics, Inc.	KR
Ilonov	CH
Image Guided Therapy Clinic	AU
Immios	NL
Immित्रa Bio GmbH	CH
ImmunoS Therapeutics AG	CH
In Virtuo Laboratories Sagl	CH
Incaptek Sàrl	CH
InCephalo AG	CH
Inchinn Therapeutics	BE
Incyte Biosciences International Sàrl	CH
INFECTA	NL
InflaRx	DE
infoteam Software AG	CH
Inhalis Therapeutics SA	CH
InkVivo Technologies AG	CH
Innosuisse	CH
Innovalex Sàrl	CH
Innovaud	CH
INOFEA AG	CH
Inotiv	DE
Inovotion	FR
Inscrenex GmbH	DE
inSEIT AG	CH
InsideReg Sàrl	CH
Insilico Medicine	CH
InSilicoTrials Technologies SpA.	IT
InSphero AG	CH
Inspiralia	ES
Institute for Translational Medicine, University of Strasbourg	FR
Institute of Computational Life Sciences / ZHAW	CH
Institute of Life Sciences, HES-SO Valais	CH
Institute of Oncology Research, Faculty of Biomedical Sciences, USI	CH
Integra Biosciences AG	CH
InterAx Biotech AG	CH
InterPharmaLink	CH
Inthera Bioscience	NL
Intralink	DE
Intrials	BR
Intsel Chimos	FR
Intu Diagnostics	DE
Invest in Skåne	SE

Participating companies

Company	Country
Invest Northern Ireland, British Embassy	DE
InvestHK	CN / DE
IOCB Tech	CZ
iOmX Therapeutics AG	DE
iOncura SA	CH
IPF Partners	CH
iPsonics	NL
iQone Healthcare Switzerland SA	CH
IQVIA AG	CH, BE, DE
Irbm SpA.	IT
Isaiah Capital	TW
ITA - Italian Trade Agency	CH
Italian Ministry of Foreign Affairs	CH
ITR Laboratories	CA
J. Lamark Asset Management SA	CH
Jacobs Switzerland GmbH	CH
Japan External Trade Organization (JETRO) Geneva Office	CH
Jarvis Advisors GmbH	CH
JB Salazar - Pharmaceutical Advisor	CH
Jeffries IP	CH
Jenal & Partners Biosafety Consulting GmbH	CH
JETRO GENEVA	CH
JFG Life Sciences Stiftung der Universität Basel	CH
Jiuzhou Pharma Europe GmbH	DE
Johnson & Johnson	CH
Julius-Maximilians-Universität Würzburg	DE
Just Evotec Biologics	FR
Juvion Life Sciences Sarl	CH
K2P PharmaCon	DE
Kamondi Bioanalytical Consultancy GmbH	CH
KBI Biopharma SA	CH / US
KCAS Bio	FR
Kellerhals Carrard	CH
KennedyFitch AG	CH
Kerna Ventures	UK
Kimialys	FR
Kisco Sarl	CH
KLIFO GmbH	DE
Knick Schweiz AG	CH
KOTRA Zurich	CH
KPMG AG	CH
KreaMedica Inc.	CA
KriSan Biotech Co., Ltd.	TW

Company	Country
Ksilink	FR
KVALITO AG	CH
KyooBe Tech GmbH	DE
L-BASE	KR
LabConnect GmbH	DE
Labcorp Central Laboratory Services Sarl	CH / UK / US
LabDeep	CH
Labor LS SE & Co. KG	DE
LaForce Business Solutions Sagl	CH
Lambda-X High Tech SRL	BE
Lancet	RU
Landmark BioVentures AG	CH
Lanmer OÜ	EE
Latvian Institute of Organic Synthesis	LV
Laurus Labs Ltd	IN
Leads to Development	FR
leadXpro AG	CH
Leanbio	ES
leap:up GmbH	DE
Lederer & Partner AG	CH
Legacy Healthcare	CH
Leman Biotech Lausanne SA	CH
Lemay.ai Inc.	CA
Let it be consulting	FR
Leukocare AG	DE
Lexogen	AT
LG Chem Europe GmbH	DE
LI-COR Biosciences GmbH	DE
Libera Bio S.L.	ES
Lichtsteiner Foundation	CH
Life Science Cares	CH
Life Science Communication AG	CH
Life Science Nation	US
Life Science Zentrum Mainz GmbH	DE
Life Science Zurich Young Scientist Network	CH
Life Sciences & Health and Digital Tech at the Canton of Aargau's location promotion agency	CH
LifeSci Advisors	CH
LifeScience ORG	UK
Light Chain Bioscience - Novimmune SA	CH
LimmaTech Biologics AG	CH
Limula SA	CH
Linical Europe GmbH	DE
Liof Pharma SLU	ES

Participating companies

Company	Country
LISCure Biosciences	KR
Livinovea GmbH	CH
Logex	NL
Lonza AG	CH
Loyens & Loeff N.V.	NL
LubioScience GmbH	CH
Lucerna Chem AG	CH
Lucid Analytics	CH
Lumerate	CA
Luminance Health GmbH	CH
Lumios	CH
Lumis International GmbH	DE
Lunaphore Technologies SA	CH
Luo Automation B.V.	NL
Lupin Manufacturing Solutions	UK / IN
LYO-X AG	CH
Lyophitech sas	FR
MaaT-Pharma	FR
MabDesign	FR
MabTree Biologics AG	CH
Mabylon AG	CH
MAPREG	FR
Maruho Deutschland GmbH	DE
Mavatar	SE
Maxia Strategies GmbH	CH
MC Services AG	DE
McArthur and Associates GmbH	CH
MCE Avocats	CH
MCTIS	CH
Medace B.V.	NL
MEDExpansion Sarl	CH
Median Technologies	FR
Medicion / CETR	CH
Medicon Valley Alliance	DK
Medicxi	CH
Medidata Solutions	UK / DE
MediTox s.r.o.	CZ
Medpace	BE
Medperion GmbH	DE
Medscape Education Global	CH / US
MedScienceSwiss AG	CH
Medvisis Switzerland AG	CH
MedXCell SA	CH
Memo Therapeutics AG	CH

Company	Country
Menarini Biotech Srl	IT
Menken Trials	EE
Merck Life Science Services	FR
Merlchamp	CH
MesenFlow Technologies Sarl	CH
Mestastop Solutions	IN
metaLead Therapeutics	CH
metaShape Pharma AG	CH
MethylX	CH
MetrioPharm AG	CH
Metronomia Clinical Research GmbH	DE
Mettler Toledo Schweiz GmbH	CH
MF Life Sciences GxP Consulting GmbH	CH
Microsynth AG	CH
MicThera Sagl	CH
Midas Pharma GmbH	DE
Mikrobiomik	ES
Miltenyi Biotec Swiss AG	CH
MimAbs	FR
MIMETAS	NL
Minaris Advanced Therapies	DE
Ministry of Economic Affairs, Transport, Agriculture and Viticulture Rhineland-Palatinate	DE
MLM Medical Labs	DE
Moderna	CH
Modiblast Pharma GmbH	DE
molab.ai	DE
Molecular Health GmbH	DE
Molecular Partners AG	CH
Molecule to Medicine	CH
Monte Rosa Therapeutics AG	CH
Moody's	UK
MoonLake Immunotherapeutics	CH
Morimatsu Italy	IT
Mosanna Therapeutics AG	CH
MPC Therapeutics SA	CH
MIRGN Advisors Sarl	CH
MSD	CH
MT-act SA	CH
MTIab srl	IT
Murata Electronics Europe B.V.	NL
MV BioTherapeutics SA	CH
Mydata-TRUST	BE
Myllia Biotechnology GmbH	AT

Participating companies

Company	Country
Myonex	FR
Nagi Bioscience SA	CH
Nanobot OÜ	EE
NanoTemper Technologies GmbH	DE
NanoVation Therapeutics	CA
Nathalie Jenni Consulting GmbH	CH
National Research Council of Canada	CA
Navignostics AG	CH
Navis Bio GmbH	CH
Nawah Scientific	PL
NBE-Therapeutics AG	CH
NCMA Consulting GmbH	CH
NegotiumBio GmbH	CH
Nerai Bioscience	CH
Netherlands Embassy	CH
Netherlands Enterprise Agency (RVO)	NL
Netherlands Foreign Investment Agency	DE
Netherlands Innovation Network	DE
Neuland Laboratories Ltd	CH
Neumirna Therapeutics	CH / DK
Neurimmune AG	CH
Neurolieve Biosciences Ltd	UK
Neurosterix Pharma Sàrl	CH
NewBiologix SA	CH
Nexco Analytics Sarl	CH
NexMR AG	CH
Nextech Invest AG	CH
nextImpact	CH
Nikon Europe B.V. Zweigniederlassung Schweiz	CH
Nitto-Denko	JP
NonStop Consulting AG	CH
NorthX Biologics Matfors AB	SE
Nouscom AG	CH
NovaGo Therapeutics AG	CH
Novalix SAS	FR
NOVARA GLOBAL ENTERPRISE	NG
Novartis Pharma AG	CH
Novigenix SA	CH
Novo Nordisk Farmacêutica do Brasil	BR
Novochizol SA	CH
NSconsulting	BE
Nubilaria Srl	IT
Numab Therapeutics AG	CH
Numaferm GmbH	DE

Company	Country
NUVISAN	DE
NVIDIA	CH
Nxera Pharma Co. Ltd., Tokyo, Basel Branch	CH
NXI Therapeutics AG	CH
NZZ	CH
OBaris AG	CH
ObelysQ SA	CH
OBN UK LTD	UK
OCCIDENT Group AG	CH
Octapharma Handelsgesellschaft mbH	AT
Office of Economic Affairs, Bern Economic Development Agency	CH
Olgram SA	CH
Olink, Part of Thermo Fisher Scientific	DE
Olon SpA	IT
OM Pharma Ltd	CH
OmiAb Inc.	US
OmnilinX Therapeutics AG	CH
Oncodesign Services	FR
Oncolipso/Pharmassist Ltd	GR
OneSource CDMO	IN
OnlyLyon Invest	FR
Ontrack Biomedical AG	CH
Onward Therapeutics SA	CH
OPTIMA pharma GmbH	DE
OptoLumina AG	CH
ORACTIVE SWISS AG	CH
ORANO MED	FR
Oregon Bioscience Association	US
Oriente SA	CH
Orio Therapeutics SA	CH
Orion Biotechnology Switzerland	CH
Orphan Drug Consulting	IE
Oryl Photonics SA	CH
Oswaldo Cruz Foundation	BR
Otsuka Pharmaceutical Companies US	US
Oxeltis	FR
Oxford Biomedica	UK
PACRT-Geneva	CH
PALL (SCHWEIZ) GmbH	CH
palleos healthcare GmbH	DE
Panome Bio	US
Panosome GmbH	DE
Paola Valinotti Aostri - Access2Health Consulting	CH

Participating companies

Company	Country
Parexel	UK / DE / FR / DK
Paterna Biosciences	US
Paulina Paiz	US
PBSS International	US
PDC Therapeutics SA	CH
Pelago Bioscience	SE
Persistent Systems	CH / UK / IN
petra-HR	CH
Pfizer Inc.	FR
Pharma-Consulting ENABLE GmbH	CH
PharmaBiome AG	CH
Pharmaboardroom	UK
Pharmabotix AG	CH
PHARMADULE MORIMATSU AB	SE
Pharmafilicates Analytics & Synthetics (P) Ltd.	IN
PharmaKorell GmbH	CH
Pharmalegacy Cl, Ltd.	CN
PharmaLex	FR / DE
Pharmaron	UK
Pharmassist Ltd Greece	GR
PharmDev Consulting	FR
Pharmidex	UK
Pharvaris GmbH	CH
Phastar	UK
Phetairos LTD	UK
Phialogics AG	CH
Philip Morris Switzerland Sàrl	CH
PHT International	US
PHT Pharmaceutical AG	CH
PHW Biotech and Start-Up Consulting	CH
PI HEALTH SCIENCES LTD	IN
Pierre Fabre	FR
Piramal Pharma Solutions	US
PlasmidFactory GmbH	DE
Playground Global	US
PLX Healthcare Services (Switzerland) AG	CH
PMS - Process Management System	CH
Pohang City	KR
PolyPeptide Laboratories	SE / FR
Populus Bio Sàrl	CH
Porsoft	FR
Porton Pharmaceutical Chemicals GmbH	CH
Positive Organizations	CH
Postrigo AG	CH

Company	Country
PPD THERMO FISHER SCIENTIFIC	UK
Pracipio Ltd	UK
Præed Pharmaceuticals Ltd	CH
Prague.bio	CZ
Prasfarma	ES
PRATIA S.A.	PL
Preclina Europe GmbH	CH
Premier Research	FR
Prevision Medicine AG	CH
PricewaterhouseCoopers	CH
ProBioGen AG	DE
Procavea Biotech AG	CH
Promega AG	CH
Prometheus Life Technologies AG	CH
Protagoras Advisory Ltd	UK
Protect Animal Health, Inc.	TW
PROTEIN ALTERNATIVES	ES
Proteintech	CH
Proteros biostructures GmbH	DE
Protevo Bio	DE
Provectis Healthcare AG	CH
Prüfer & Partner mbB Patentanwälte Rechts-anwälte	DE
PSI CRO AG	CH
PSM GmbH - Your Pharma CDMO	DE
PULSE developed by EPIC SUISSE SA	CH
PulseSight Therapeutics	FR
Pureos Bioventures	CH
Q1 Scientific Belgium - a Cambrex company	BE
Qanatpharma AG	CH
QBDC GmbH	CH
Qiagen GmbH	DE
QPS	FR / NL
QUALIBLOOD	BE
Quality Assistance	BE
Quant Biomarkers AG	CH
Quantoom Biosciences	BE
QUANTRO Therapeutics	AT
Quartz Bio SA	CH
QUINTA-ANALYTICA S.R.O.	CZ
Quinz	BE
Quotient Sciences	UK
QurieGen B.V.	NL
R&G PharmaStudies Co., Ltd.	CN

Participating companies

Company	Country
RadaHaim	KR
Rambam AG	CH
Raumedic Estonia AS	EE
RD-BIOTECH	FR
RDI Partners	AU
RDP Pharma AG	CH
Reaction Biology Europe GmbH	DE
Regulatory Pharma Net Srl.	IT
Release Therapeutics SA	CH
REM Analytics SA	CH
Renaldee AG	CH
Rentschler Biopharma SE	DE
Resea Biotec GmbH	CH
Reseau Lieu	BE
RHA Communications	CH / UK
Richmond	UK
Risklick AG	CH
Roche Glycart AG	CH / FR
Rockstone Engineering Switzerland Sarl	CH
ROHTO Pharmaceutical Co., Ltd.	JP
RV Invest	DE
S4BT srl	IT
Sai Life Sciences	UK / DE
SAKK	CH
salamanderU	BE
Salvina Therapeutics AG	CH
Sanofi	FR
Santen SA	CH
Santhera Pharmaceuticals (Switzerland) AG	CH
Sartorius	BE
Sartorius Stedim Switzerland AG	CH
SAIT AxLR	FR
SAIT Conectus	FR
SaxoCell	DE
Saxony Trade & Invest	DE
Scantox Denmark ApS	DK
Scendea Ltd.	UK
Scene Partners AG	CH
SCHOTT Pharma Schweiz AG	CH
scienceindustries	CH
SCIENION GmbH	DE
Sciential	NL
Sciomics GmbH	DE
Scrubin OÜ	EE

Company	Country
SCT Cell Manufacturing - SCTbio	CZ
SEAL Therapeutics AG	CH
Security Pattern Srl.	IT
SEED Biosciences SA	CH
Seerave Foundation	CH
Seito Biologics AG	CH
Selmod GmbH	CH
Selvita	PL
Senn Resources AG	CH
Sense4Med Srl.	IT
SEQENS	FR
SERENITE-Forceville	FR
Serum Life Science Europe GmbH	DE
Service Biotech Srl	IT
Service de l'Économie de Neuchatel	CH
seventure partners	FR
SGDL HEALTH SA	CH
SGS	FR / ES
SGS Analytics Germany GmbH	DE
SGS Analytics Switzerland AG	CH
SGS Life Sciences Geneva	CH
SGS Vitrology	UK
Shandong Jincheng Pharmaceutical Group Co., Ltd.	CN
Shanghai Medicilon Inc	UK
Shape Biopharmaceuticals GmbH	CH
Shimadzu Schweiz GmbH	CH
SICC	CH
SICTIC	CH
Sidrapex	CH
Siegfried Dinamiqs AG	CH
Simbec-Orion	UK
Sincere Pharmaceutical Group	UK
Sindusfarma	BR
Single Cell Discoveries	NL
Singleron biotechnology	DE
Sintetica S.A.	CH
Siron Clinical	NL
sitem insel AG	CH
SIX Swiss Exchange AG	CH
SK PHARMTECO	FR
SKM-IP Schmid Krauß Kuttenkeuler Malescha	DE
Schieler Patentanwälte PartGmbH	DE
Skyepharma	FR

Participating companies

Company	Country
Skyvor Medical AG	CH
SLA Pharma	UK
Slate Mountains Capital GmbH	CH
SmaBio Labs	US
SmiLe Venture Hub	SE
Sofinnova Partners	UK
Softmining Srl	IT
Solid State Pharma Inc.	CA
Solid Technologies S.L	ES
Solvias AG	CH
Somagenetix AG	CH
Sophia Genetics SA	CH
Sotio Biotech AG	CH
SP Clinical Consulting AG	CH
SpacePharma SA	CH
Spanish Embassy in Bern	CH
Specific Pig SI (specipig)	ES
SPILLO di Alessandro Di Domizio	CH
Springer Nature	UK
ST Pharma GmbH	CH
Stada Arzneimittel AG	DE
StageBio	UK / US
STALICLA SA	CH
Startupticker.ch	CH
Sterling Pharma Solutions	UK
Sterne Kessler	US
Stifel (Schweiz) AG	CH
Stifel Europe Advisory GmbH	DE
Stiftung grow	CH
STR AG	CH
STRASSBURGER FILTER	DE
StratiCELL	BE
Stromal Therapeutics AG	CH
Studio Torta SpA.	IT
SubjectWell Inc.	US
Sulista GmbH	CH
SunRegen Healthcare AG	CH
Superlab Suisse AG	CH
Supply Chain Operations SA	CH
SUPSI-DTI-ISTEPS	CH
SVDI	CH
Swabot Solutions, LLC	US
SwAPP	CH
SwedenBIO	SE

Company	Country
Swedish Orphan Biovitrum	SK
Swiss Biotech Association	CH
Swiss Broadcasting Corp (swissinfo.ch)	CH
Swiss Business Hub China	CN
Swiss Business Hub Japan / Embassy of Switzerland in Japan	JP
Swiss Federal Institute of Intellectual Property	CH
Swiss Healthcare Startups	CH
Swiss Life AG	CH
Swiss Rockets AG	CH
SwissBiotechSolutions	CH
Swissmedic Swiss Agency for Therapeutic Products	CH
SwitchKine AG	CH
Switzerland Global Enterprise	CH
Switzerland Innovation Park Ticino	CH
Sygnature Discovery Limited	UK
Symbiosis	UK
Symeres	NL
SynapCon GmbH	DE
Synapto Ventures	SG
Synendos Therapeutics AG	CH
Syneos Health Switzerland GmbH	CH
Synexa Life Sciences	UK
Syngene International Ltd	IN / DE
SYNGULON	BE
Syntegris Consulting	FR
Synvia	BR
Syspro Automation S.L.U.	ES
T-Oncology AG	CH
T3 Pharmaceuticals AG	CH
Taiwan Bio Industry Organization	TW
Tak BioSuisse	CH
Takis Biotech Srl.	IT
Talisto GmbH	CH
Tandem Therapeutics AG	CH
Taros Chemicals GmbH & Co. KG	DE
Tartu Biotechnology Park	EE
Tataa Biocenter	SE
TATUM bioscience	CA
TBD Pharmatech OÜ	EE
TCG LIFE SCIENCES	IN
Tebu-bio GmbH	DE
Tecan	CH

Company	Country
Technical University of Munich (TUM)	DE
TECregen AG	CH
Teijin Holdings Europe B.V.	NL
Telemedicine Technologies	BE
Tenity Group AG	CH
Tenpoint Therapeutics GmbH	CH
Terrapinn Holdings Ltd	UK
TFS HealthScience	ES / SE
TFS Trial Form Support GmbH	DE
The Bloc Switzerland AG	CH
The European Pharmaceutical Students' Association	ES
The Life Science Cluster	NO
Theradex Oncology	UK
therainnova AG	CH
TheraPPI Bioscience SA	CH
Thermo Fisher Scientific	US
Thermo Fisher Scientific Biologics Lengnau	CH / IT / UK
Thermo Fisher Scientific Life Technologies	CH
Tigen Pharma SA	CH
Tigermed Swiss AG	CH
Tiofarma BV	NL
TissueLabs Sagl	CH
TNO	NL
TomoeGawa Europe B.V.	NL
Topadur Pharma AG	CH
TopLink GmbH	CH
Toxicology Consultant	DE
TPL Path Labs GmbH (StageBio)	DE
Trans-Duodenal Concepts GmbH	DE
TransHeps AG	CH
Trialize AG	CH
Tridek-One Therapeutics SAS	CH
TRIGA-S GmbH	DE
Trillome GmbH	CH
TruKing Technology	IT
Tubulis GmbH	DE / CH
TUNECT CRO	AM
Turbine Simulated Cell Technologies Ltd.	UK
TwinEdge Bioscience SA	CH
UBS Switzerland AG	CH
UCB Pharma AG/UCB Farchim SA	CH / BE
Ultimate Medicine AG	CH
Umlaut.bio GmbH	CH

Company	Country
uMotif Limited	UK
UNIL-CHUV Knowledge Transfer (FACTT)	CH
Unipharma SA	CH
Universal Medica Group	FR
Università della Svizzera italiana	CH
University of Basel	CH
University of Bern	CH
University of Edinburgh	UK
University of Pisa	IT
University of Zurich	CH
Upperton Pharma Solutions	UK
Vaccentis AG	CH
Vaderis Therapeutics AG	CH
Vanarix SA	CH
Vandria SA	CH
Vaudaux-Eppendorf AG	CH
Veeda Lifesciences	GR
Velalabs	AT
Velsera	US
Venn Life Sciences ED B.V.	NL
VentriLabs	SE
Venture Valuation	CH
Venturelab	CH
Veristat	CH
Veritus Research	AU
Versameb AG	CH
VERSANT VENTURES	CH
Vetter Pharma-Fertigung GmbH & Co. KG	DE
Viatris	BE
Viedoc Technologies AB	SE
ViferaXS GmbH	DE
Viopas Venture Consulting GmbH	CH
Vir Biotechnology, Inc. (formerly Humabs BioMed AG)	CH
VIRBAC	FR
ViridisGroup Srl	CH
VISCHER AG	CH
Visitor	CH
Vitalograph	IE
VitroScan	NL
VIVEbiotech	ES
Vivtex GmbH	CH
Volv Global SA	CH
Vossius & Partner	CH

Company	Country
VP & GM Head Europe	CH
VTU Engineering Schweiz AG	CH
VUGENE	LT
WACKER	DE
Walder Wyss AG	CH
Wallonia Export & Investment Agency	BE
Wallonie-Bruxelles International - Embassy of Kingdom of Belgium	BE
WELT Corp., Ltd.	KR
Wemedoo AG	CH
WEP Clinical	UK
White Raven	BE
Wipro Limited	US
Wipro Ltd. Geneva branch	CH
Wirtschaftsförderung Luzern	CH
Witt/Kieffer Schweiz AG	CH
Witt/Kieffer	UK
World Courier	ES
Worldwide Clinical Trials	UK
WuXi AppTec	CH / UK
WuXi Biologics	CN / CH / US
Wuxi XDC	CN
Wyss Center for Bio and Neuroengineering	CH
Wyss Zurich	CH
Xcenda Switzerland GmbH	CH
XCubeBio AG	CH
Xentech	FR
xFOREST Therapeutics	JP
XGEN Venture SGR S.p.A.	IT
Xlife Sciences AG	CH
Xtalpi Inc.	CN
YAYA Capital	CH
Ymmunobio AG	CH
YNIOS Pharma Srl	BE
YONI Solutions SA	CH
Your Special Delivery Service AG	CH
Ypso Facto Luxembourg S.A.	LU / FR
Ypsomed AG	CH
YSIOS CAPITAL	ES
YUMA Capital Partners AG	CH
YUMAB GmbH	DE
Zambon Biotech SA	CH
Zasya Life Sciences	IN
ZETA GmbH	AT

Company	Country
Zuger Capital AG	CH
Zultak Consulting SAS	FR
Zurich University of Applied Sciences	CH
Zymo Research Europe GmbH	DE

Sponsors, exhibitors & partners

Main sponsors



Sponsors



Sponsors, exhibitors & partners



Supporting partners



Media partners



Host and event manager



Logistics and marketing partner



SWISS+ BIOTECH™

Collaborate with us and use the power
of our networking platforms

Save the date!



Swiss Biotech Day: May 4–5, 2026

For international networking at one of the leading global biotech conferences, with thousands of guests



Boosting global visibility

By promoting biotechs in the Swiss Biotech Directory, by disseminating their news, and with success stories



Financing and partnering

By connecting Swiss R&D biotech companies with global investors and industry partners on Swiss Biotech Ventures



Finding talent internationally

By matching Swiss job opportunities and talents on Swiss Biotech Orbit



Foster international collaboration

By uniting foreign biotech clusters with the Swiss biotech ecosystem through our Global Village



Professional development and education

At the Swiss Biotech Association Academy offered by academic institutions & regular Swiss Biotech Insight meetings

Save the date!

SWISS BIOTECH DAY 2026

© Swiss Biotech Association

May 4–5, 2026
Congress Center Basel

Are you interested in increased visibility at the next Swiss Biotech Day?

We offer various sponsorship opportunities designed to promote your brand, products, services and build partnerships.

Contact us to discuss your ideas!
Meet our team today at the help desk
or contact us at info@swissbiotechday.ch.



Sign in on our website at
swissbiotechday.ch
and stay updated about any news.

Host & event manager:



Logistics & marketing partner:

bamconn